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  The incidence of infection and non-union in severe musculoskeletal fractures 
continues to plague the medical community. This work investigated calcium sulfate (CS)-
chitosan composite scaffolds with dual drug delivery capabilities. The aim of this 
dissertation is to investigate potential strategies for a dual delivery composite scaffolds 
that will allow for sufficient delivery of two therapeutic agents to control infection and 
regrow bone.  
 Initial work focused on a chitosan microspheres-composite for delivery of antibiotics 
and growth factors. The dual delivery of antibiotics from both the CS and chitosan 
components was an approach to treat polymicrobial infections, while the dual delivery of 
an antibiotic from CS and growth factor from the chitosan component was aimed at bone 
regeneration to treat fractures that require additional therapies to stimulate bone healing 
while preventing an infection. The effectiveness of the dual antibiotic loaded scaffold to 
eliminate infection was depended on the amount of drugs loaded and if the drugs were 
delivered together or separate. Vancomycin released from the dual loaded scaffold 
sustained almost 5 weeks of bacterial growth inhibition, whereas the amikacin release 
inhibited bacterial growth for only one day. The composite scaffold loaded with 
vancomycin and a growth factor, rhBMP-2, had extended bacterial inhibition and killing. 
The rhBMP-2 release was delayed 2 days and had a low-level extended elution over 6 
weeks. The activity of rhBMP-2 could not be determined, and it was found that the level 
of rhBMP-2 released might not have been high enough to stimulate cells in vitro. To 
	 vii	
increase the rhBMP-2 elution, mechanical integrity, and make channels for 
vascularization ingrowth, chitosan meshes were substituted for the microspheres in the 
third study. While the meshes increased the vancomycin elution, no change in rhBMP-2 
elution was found. The meshes did improve the ability of the scaffold to remain intact 
under mechanical forces. 
 While further research into the biological activity of released rhBMP-2 and in vivo 
evaluation of the scaffold must be performed, our research demonstrates the successful 
dual delivery of therapeutic agents from a composite scaffold that could be used as an 





 The purpose of this research was to develop and evaluate a novel composite scaffold 
with drug delivery capabilities for use in severe musculoskeletal fractures. The work 
presented in this dissertation is comprised of manuscripts, which are published or will be 
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recombinant human bone morphogenetic protein-2”. Journal of Material Science. 
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 Traumatic bone fractures, birth defects, bone tumor removal, or other large 
musculoskeletal wounds, can be difficult for the body to heal on its own. Often surgeries 
and medical interventions, such as bone grafts, are necessary due to large bone voids and 
lack of sufficient vasculature and blood flow to the wound [1,2]. In the US alone over 8 
million bone fractures occur each year and over 1 million surgeries are performed to treat 
severe orthopaedic traumas including bone excisions, grafting and fracture repair [3,4]. 
The economic burden of musculoskeletal treatments in 2004, including hospital costs, 
and salary loss was estimated at $26.65 billion/year, and is increasing every year due to 
the aging population and continued military engagements [1,5].  
 Complex musculoskeletal injuries can become infected with a variety of pathogenic 
bacteria at the time of injury, during surgery or in the hospital [6–8]. Infections can 
impair healing, lead to repeated surgeries, result in sepsis, limb amputation, and even loss 
of life [9–13]. Open fractures are particularly sensitive to infection and occur when skin 
and soft tissue are significantly damaged and expose the wound to the surrounding 
environment [14–16]. While the reported rates of infection from internal fixation devices 
are 2%-5%, infection in open fractures typically varies from 20-65% [2,17–19]. 
Additionally, the majority of combat extremity wounds are open fractures [11], and they 
are often plagued with non-union and rates of infection up to 77% [20].  
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 Pathogens commonly responsible for infections in musculoskeletal injuries include 
both Gram-positive and Gram-negative bacteria such as Pseudomonas aeruginosa (P. 
aeruginosa), Escherichia coli, Staphylococcus epidermidis and Staphylococcus aureus 
(S. aureus) [21–24]. Chronically infected fractures are more difficult to treat, and can be 
at greater risk for polymicrobial infections, where one or more bacterial or fungal species 
are present [21,25]. Similarly, an increase in combat related polymicrobial infections has 
been seen due to drug resistance in bacteria such as methicillin-resistant S. aureus 
(MRSA) [20,25]. Thus, there is a critical need for therapies that can treat and prevent 
musculoskeletal wounds from single and polymicrobial infections to improve patient 
outcomes and reduce the economic burden. 
 Current treatment strategies for traumatic bone injuries include irrigation and 
debridement to help remove infectious agents, foreign bodies and necrotic tissue, wound 
stabilization and closure, and administration of systemic antibiotics [12,13,19,26–28]. 
Normal bone healing occurs in stages; first a blood clot is formed, then inflammation 
occurs, next a soft callus is formed which is transformed into bony callus, and overtime 
this callus is remodeled into bone [13,29,30]. If any one of these repair phases is 
inhibited, fracture healing will be delayed or prevented, resulting in a non-union [29,30]. 
In traumatic musculoskeletal injuries, severely damaged vasculature affects the normal 
healing pathway by blocking the transport of cells to the wound, and it will also inhibit 
the delivery of systemic antibiotics which subsequently increases the chances of an 
infection in the wound [2,31,32]. Additionally, if the bone defect is too large, cells will 
not be able to mitigate the healing process and regeneration will not occur. Thus, when 
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the musculoskeletal tissue damage is severe, adjuvant therapies such as delivery of local 
antibiotics and growth factors in a bone graft may be necessary [2,12,13,19].  
 An ideal bone graft material for the treatment of large fractures should be 
biocompatible, bio-resorbable, osteoconductive, able to maintain a 3D structure for 
cellular support, easy to use, cost effective, and a suitable carrier for multiple different 
therapeutic agents [1,33,34]. Bone grafts for this purpose have been developed from 
primarily two types of materials: ceramics and degradable polymers.  
 Ceramic materials such as calcium phosphate (CPC), hydroxyapatite (HA) and 
calcium sulfate (CS) have been extensively studied as drug delivery devices for infection 
control in fractures [1,2,35]. They are osteoconductive, biodegradable, readily available, 
inexpensive and can be manufactured into a variety of shapes or be made injectable when 
used in combination with other materials [1,36]. Calcium phosphates are relatively brittle 
and can take 26-86 weeks to absorb into the body [1,35]. While calcium sulfate materials 
are sometimes associated with wound drainage, it has not been reported to prevent 
healing [37,38]. Additionally, calcium sulfates have a fast resorption rate of 4-12 weeks 
and excellent drug delivery capabilities making it a good candidate for a graft material in 
fracture repair [35,39].  
 Calcium sulfate (CS) is a naturally occurring mineral, gypsum, and through a drying 
process called calcination it is converted to CS hemihydrate form [40,41]. With the 
addition of water, CS is converted back to a dehydrate configuration and through a mild 
exothermic reaction sets into a hardened form. !"!"! ∙ 1 2!!! + 1 1 2!!! ↔
!"!"! ∙ 2!!!. There are two forms of CS hemihydrate: α, the densest form is used in 
medical applications, and β, a less dense form that requires more water for conversion is 
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commonly used for commercial materials. CS has been used as a bone filler since 1892 
and was first approved by the Food and Drug Administration as a surgical graded calcium 
sulfate called “Osteoset” in 1996 [37,40]. CS was reported by Ricci et al. to leave behind 
an apatite “bioactive lattice” upon degradation upon which bone cells can attach and 
proliferate in vivo. Additionally, it has been reported that calcium ions may aid in 
osteoblastic differentiation [40,41]. CS has been extensively studied in vitro and in vivo 
and is an effective antibiotic delivery system for compounds such as amikacin, 
vancomycin, tobramycin, gentamicin, cefazolin and rifampicin [41–47].  
 Polymers offer a variety of advantages in tissue engineering and have been widely 
investigated as local drug delivery systems [2,19,48–50]. There are two main classes of 
degradable polymers, synthetic and natural. Synthetic polymers such as poly(lactic acid) 
(PLA), poly(lactic-co-glycolic acid) (PLGA),  poly(e-caprolactone) (PCL), 
polyhydroxyalkanoates, polyurethane (PUR) and poly(2-hydroxyethy methacrylate) 
(pHEMA) have many variables that can be adjusted during manufacturing to achieve 
desired properties [2,19,48]. Thus, they have been used in drug delivery to achieve 
optimal loading and delivery. PLA, PLGA and PUR based scaffolds have been shown to 
deliver stimulatory amounts of bone morphogenetic protein-2 (BMP-2) to repair bone 
defects in vivo [19,51]. Additionally PLGA, pHEMA and PUR based scaffolds have been 
reported to release active levels of antibiotics (tobramycin, doxycycline, gentamicin and 
vancomycin) for 2-8 weeks in vitro and in vivo [19,52–55]. While synthetic polymers 
offer customizable drug release kinetics they often lack the structural integrity needed for 
bone scaffolds, the ability to promote bone healing and can have weak interactions with 
bone tissue, causing graft rejection and inflammation [2,19,28,48,50]. Therefore, 
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synthetic polymers are often used in combination with ceramic materials and growth 
factors to overcome these limitations [19,48–50].   
 Unlike synthetic polymers, natural polymers such as collagen, fibrin, chitosan and 
alginate have the advantage of being easily recognized by the body, and supporting 
cellular adhesion and proliferation [2]. However, as stand-alone bone graphs, natural 
polymers are also typically not strong enough to be used in a large bone defect, can be 
limited in supply and have some consistency issues between batches [35,56]. The medical 
device InFUSE® uses a collagen sponge in combination with a titanium cage to delivery 
BMP-2 for enhanced bone regeneration in the spine [31,49,57]. As a result of the 
supraphysiological doses typically used in collagen sponges to elicit the necessary in vivo 
tissue responses, negative side effects such as uncontrolled bone growth and ectopic bone 
growth in an unwanted area are a major concern [49,58]. Thus, delivery kinetics should 
be manipulated to achieve the desired elution effect with reduced side effects for any 
bone scaffold system. Chitosan is one natural polymer that has been extensively studied 
due to its customizability for drug delivery applications [59–64].  
 Chitosan is the deacetylated product of the natural biopolymer chitin, a 
polysacharride found primarily in the exoskeleton of shellfish. When more than 50% of 
the acetyl groups are removed from chitin, the polymer is considered to be chitosan and is 
composed of both acetylated and deacetylated β -(1-4)-2-amino-2-D-glucosamine units 
[60,65,66]. The degree of deacetylation (DDA), molecular weight (MW) and 
crystallinity, can be used to control the rate of degradation and chitosan can be easily 
manipulated into a variety of forms such as microbeads, nanobeads, fibers, meshes, and 
sponges [60,65–68]. Chitosan is also biocompatible, supporting cellular growth and 
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function, and can be used as a drug delivery device for many therapeutic factors 
[60,62,69–72]. Since the mechanical strength of chitosan (in any form) is much less than 
of cancellous bone (10-2000 MPa) it is not ideal as a stand-alone device for large 
musculoskeletal fractures [73].  
 Many different chitosan-ceramic composites have been investigated. Chitosan 
sponges, fibers, meshes, gels and microspheres have been incorporated with calcium 
phosphate, hydroxyapatite and calcium sulfate materials [63,71,74–79]. In vitro, CPC-
chitosan composites have been reported to facilitate proliferation and differentiation of 
bone cells [71,75,80]. Additionally, several studies have found that the addition of 
chitosan (sponge, fiber, meshes) into ceramic materials also improves the mechanical 
strength of the bone grafts [75,81–84]. In rabbit and dog models CPC–chitosan, HA-
chitosan and CS-chitosan grafts showed good tissue ingrowth and bone repair 
[77,83,85,86]. Although these composite scaffolds have shown good biocompatibility, in 
an infected musculoskeletal wound there is an additional need to fight infection and 
promote bone regeneration.  
 Bone grafts that are also able to locally deliver therapeutic agents can inhibit bacterial 
colonization independent of circulation and have no associated organ toxicity as seen 
with high doses of systemic antibiotics [15,51,87]. Additionally, developing a graft that 
can be prepared and loaded with therapeutic agents in the operation room allows for 
tailored treatment specific to the patient. This customization is beneficial because 
fractures can be infected with a variety of both Gram-positive and Gram-negative 
bacteria [15,22,25]. In patients that present polymicrobial infections, treatment strategies 
with two or more antibiotics may be necessary. While many types of antibiotics are used 
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to treat orthopaedic infections, amikacin and vancomycin are of particular interest 
because they have both shown low toxicity on osteogenic cell viability and activity 
[20,21,88,89]. Amikacin is a broad-spectrum antibiotic that is active against Gram-
negative and Gram-positive bacteria, and the antibiotic vancomycin, is active against 
Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), 
which poses a severe threat to fracture healing [20,90]. The co-delivery of amikacin and 
vancomycin from calcium sulfate and a polymer gel has been studied [91,92]. Atilla et al. 
found that when antibiotics were combined in one calcium sulfate pellet, the elution rate 
was much higher, and the effectiveness against bacteria had a shorter duration as 
compared to single loaded pellets. They suggested this was due to increased porosity in 
the CS when both antibiotics were used [91]. Conversely, Thomas et al. reported slower 
and extended elution of vancomycin, amikacin and clindamycin from a R-gel polymer. 
They found the eluents were bioactive against S. aureus during a 10 day study [92]. No 
loss in activity was found for either antibiotic when co-delivered, indicating that 
amikacin and vancomycin could be used together to treat Gram-positive and Gram-
negative polymicrobial infections [91,92]. However, the elution and activity duration 
reported is shorter than the recommended 4-6 weeks duration of local delivery, based on 
the time it takes for revascularization of bone in animal studies [2,93,94]. Thus, a bone 
graft that could control and extend the dual antibiotic elution over a longer period of time 
is needed.  
 Bone formation and regeneration is tightly regulated by three groups of signaling 
molecules 1) pro-inflammatory cytokines 2) transforming growth factor-beta superfamily 
members and 3) angiogenic factors [30]. Bone morphogenetic proteins (BMP) are 
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members of the transforming growth factor-beta family that initially recruit stem cells to 
the fracture site where they initiate blood vessel formation and differentiation of stem 
cells into osteoblasts [30,95–97]. There are currently about 15 identified members of the 
BMP family [96]. Both BMP-2 and BMP-7 are commonly studied for fracture repair. 
BMP-2 initially recruits cells and acts later during osteogenesis and chondrogenesis, 
whereas BMP-7 acts only on bone differentiation [2]. Since BMP-2 is active through the 
stages of healing, studies have shown that the extended delivery of BMP-2 is more 
effective than an initial bolus release [58,96,98,99]. A drawback of current BMP-2 use is 
that often supraphysiological doses are needed to compensate for poor release kinetics, 
fast inactivation in vivo, and lack of extended delivery of biological active growth factor 
[49,58]. These high doses have been associated with adverse reactions such as excessive 
bone formation, ectopic bone formation, and due to the expense of BMP, high doses 
greatly increase the cost of treatment [97,100,101]. Combination delivery devices that 
can optomize the BMP-2 delivery could be a solution to overcome these limitations.  
 The local delivery of both a growth factor and an antibiotic in a bone graft is 
attractive for use in complex musculoskeletal fractures. Studies have shown that when 
co-delivered from polymers, polymer coating on a K-wire or in CS, BMP-2 remained 
active in the presence of an antibiotic [51,53,102–104]. Similarly, in vivo results have 
indicated that BMP-2 and an antibiotic co-delivered from collagen sponges, a CS 
scaffold, and polymers is effective in augmenting new bone formation between 4-12 
weeks [51,102,103,105]. Guelcher et al. investigated a PUR scaffold loaded with both 
vancomycin and BMP-2 in vivo. The most significant bone growth in the rat femoral 
defect was found from scaffolds loaded with both BMP-2 and vancomycin, compared to 
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BMP-2 loaded scaffolds or controls. This indicated that in the presence of infection, new 
bone regeneration was inhibited [58]. While these studies report that co-delivery of 
antibiotics with growth factors can result in bone healing and infection control, some 
required a supraphysiological dose of BMP [102], lack the ability to customize the 
scaffold in the operating room [51,53,103], and had unpredictable degradation rates that 
could interfere with bone regeneration [53,58,105]. The use of a composite ceramic-
degradable polymer bone graft may help to overcome these limitations.  
Hypothesis 
 
 Currently, there is a clinical need for a dual drug delivery bone scaffold to have 1) 
good drug release kinetics for extended therapeutic activity and reduced side 
effects/expense, 2) degradation rates similar to bone growth, 3) the ability to maintain 3D 
space, and 4) the flexibility of preparation and customization by the surgeon for 
individualized treatment. In this dissertation, we investigated in vitro the dual delivery of 
two antibiotics and the combination of a growth factor and an antibiotic from a composite 
calcium sulfate-chitosan based scaffold with the aim of extended antibiotic and growth 
factor elution for infection control and cellular indication of active growth factor. 
Optimization of growth factor delivery was pursued with the use of both chitosan 
microspheres and wet-spun fiber-meshes. The scaffolds were designed with the idea that 
they could be used as a point-of-care devices, could be customized drug delivery system 
loaded with a variety of therapeutic agents, and would eliminate the need for 
supraphysiological doses of growth factor. Additionally, the materials for this scaffold 
were chosen because they have the ability to maintain a 3D structure where bone cells 
can attach and lay down new bone matrix, and they have good degradation properties.  
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Our overall hypothesis is that composite calcium sulfate-chitosan scaffolds will be able to 






ELUTION OF AMIKACIN AND VANCOMYCIN FROM A CALCIUM 






Infections in complex orthopaedic wounds can delay or inhibit healing and can be very 
difficult to treat (Thomas et al. 2005; Noel et al. 2010; Nair et al. 2011). Together, 
infection and severe tissue damage can reduce blood flow, which can prevent the 
necessary inflammatory and reparative cells from accumulating and acting at the wound 
site (Nair et al. 2011). Reported infection rates after surgery and trauma range from 1-
55% and open fracture infections range from 10-50% depending on the severity of the 
wound (Patzakis and Wilkins 1989; Jain and Panchagnula 2000; Zalavras et al. 2005; 
Anderson et al. 2011; Wenke and Guelcher 2011; Hogan et al. 2013). Common 
pathogens responsible for infecting these injuries include both Gram-positive and Gram-
negative bacteria such as Pseudomonas aeruginosa, Escherichia coli, Staphylococcus 
epidermidis and Staphylococcus aureus (Gentry 1997; Kobayashi et al. 2008; 
Hatzenbuehler and Pulling 2011; Hogan et al. 2013). Treatment can be particularly 
challenging in wounds containing polymicrobial bacterial species and/or resistant species 
such as methicillin-resistant S. aureus (MRSA). In addition, identifying the infecting 
organism is time-consuming and can be misleading when results are falsely negative 
(Brady et al. 2006; Kobayashi et al. 2008; Hogan et al. 2013; Parvizi et al. 2014).  
Polymicrobial orthopaedic infections may require more than one antibiotic for 
sufficient treatment. Local delivery devices loaded with antibiotics have been 
investigated due to toxicity issues with systemic delivery and reduced vasculature in the 
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wound (Zilberman and Elsner 2008; Noel et al. 2010; Rathbone et al. 2011; Schlickewei 
et al. 2014), but only a handful of dual delivery systems have been reported 
(Lodenkämper et al. 1982; Penner et al. 1996; Bucholz 2002; Phillips et al. 2007; Atilla et 
al. 2010; McPherson et al. 2013; Sakamoto et al. 2013; Howlin et al. 2015). A dual-
antibiotic-loaded local delivery device made from polymethylmethacrylate (PMMA) was 
investigated by Penner et al. and Phillips et al. and found to have a much faster rate of 
elution than the single antibiotic loaded devices (Penner et al. 1996; Phillips et al. 2007). 
Although PMMA has been used to deliver antibiotics, it is not an ideal delivery device 
since it requires additional surgery for removal, can only be used with certain heat-stable 
antibiotics, and can elute low-level antibiotics that contribute to bacterial resistance.  
The limitations of PMMA have resulted in ongoing research on degradable drug 
delivery systems, such as calcium sulfate, which can be loaded with a wider variety of 
antibiotics than PMMA (McLaren 2004; Wenke et al. 2006; Gogia et al. 2009; Thomas 
and Puleo 2009; McConoughey et al. 2015). Amikacin and vancomycin were co-
delivered from a degradable calcium sulfate scaffold by Atilla et al. (Atilla et al. 2010). 
They reported results similar to PMMA studies; faster elution with the dual-loaded 
scaffold compared to single loaded scaffolds. The fast elution rates of dual-loaded 
scaffolds may be considered a shortcoming for local delivery systems because of a loss of 
long-term antibiotic and therapeutic effectiveness. The reason for the fast elution rate of 
dual-loaded scaffolds is not clear. Speculations from literature are that the presence of 
two antibiotics results in an increased porosity of the scaffold and allows for faster 
elution through the pores, and/or that the potential for chemical interactions between the 
antibiotics and the scaffold may increase scaffold degradation rates leading to faster 
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antibiotic release (Penner et al. 1996; Phillips et al. 2007; Atilla et al. 2010). 
Additionally, high levels of antibiotic incorporation can interfere with complete 
conversion of calcium sulfate to the dehydrate form, possibly causing faster degradation 
and faster antibiotic elution (Richelsoph et al. 2007; Thomas and Puleo 2009; Atilla et al. 
2010). Regardless of the reason, current research reports that dual-loaded scaffolds elute 
antibiotics faster than scaffolds with a single antibiotic. However, extending local 
antibiotic administration for 4-6 weeks is desired to completely eradicate and prevent 
serious infections. This time frame comes from clinical studies with antibiotic therapy 
and the time necessary for revascularization of bone in animal studies (Lew and 
Waldvogel 1997; Lazzarini et al. 2004; Nair et al. 2011). Additionally, polymicrobial 
infections may require more than one antibiotic for treatment. Thus, there is a need for a 
scaffold system that can deliver two antibiotics with extended elution times while 
retaining necessary properties to support new bone growth.  
To address the extended dual-delivery problem, a scaffold composed of antibiotic-
loaded chitosan-nano hydroxyapatite (C-nHA) microspheres embedded into antibiotic-
loaded calcium sulfate (CaS) paste was investigated. Calcium sulfate was chosen because 
it is a commercially used bone graft material, has the versatility to be loaded with 
multiple different antibiotics, can be manipulated by the surgeon at the point of care, and 
can easily act as a binder for other materials such as microspheres (Wichelhaus et al. 
2001; Thomas et al. 2005; Richelsoph et al. 2007; Thomas and Puleo 2009; Parker et al. 
2011). Drug-loaded C-nHA microspheres were selected because they have been shown to 
be effective for local drug delivery, and they may also be easily incorporated into other 
materials such as CaS paste, which can act as a temporary barrier to fluid flow from the 
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surrounding environment and slow/extend drug release from the microspheres (Pecora et 
al. 1997; Thomas and Puleo 2009; Reves et al. 2009; Doty et al. 2014). The C-nHA 
microspheres may also provide a necessary framework for tissue regeneration, since a 
limitation of calcium sulfate is a fast resorption rate (Chesnutt et al. 2009; Thomas and 
Puleo 2009; Dash et al. 2011; Reves et al. 2012). By loading antibiotics into two 
individual parts of a composite scaffold, we hope to eliminate or minimize interactions 
between the two therapeutic agents and to provide an extended elution profile for both 
antibiotics.  
In order to develop effective treatment of polymicrobial wounds, a co-delivery system 
for two antibiotics from a bone graft substitute was fabricated from a composite of CaS 
and C-nHA microspheres. Two antibiotics, amikacin and vancomycin, were used as 
model therapeutic agents since they provide coverage over both Gram-positive 
(vancomycin and amikacin) and Gram-negative (amikacin) pathogens. These antibiotics 
were also selected as they are commonly used to treat infections such as MRSA and have 
lower toxicity issues compared with other antibiotics (Edin et al. 1996; Zilberman and 
Elsner 2008; Jackson et al. 2009; Atilla et al. 2010; Noel et al. 2010; Rathbone et al. 
2011; Wenke and Guelcher 2011). While there is a potential for antagonistic, additive, or 
synergistic interactions when co-delivering two antibiotics, no change in activity for 
vancomycin or amikacin has been reported when co-delivered (Atilla et al. 2010; Noel et 
al. 2010; Thomas et al. 2011; Sakamoto et al. 2013). Potential effects of the composite 
scaffold on antibiotic activity will be examined. It is hypothesized that this composite 
scaffold will be able to deliver antibiotics for an extended period of 4 weeks at 
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biologically active levels and that the incorporation of C-nHA microspheres will aid in 
extending the time course of elution of therapeutic agents.  
2. Materials and Methods  
 
2.1 Chitosan-HA Microsphere Fabrication 
  
A previously described co-precipitation method was employed for the fabrication of 
the composite chitosan-nano hydroxyapatite (C-nHA) microspheres (Chesnutt et al. 
2009). Briefly, 3.57 g 80% DDA chitosan powder (260 kDa, Primex EHF, Siglufjordur, 
Iceland) was dissolved in 84 mL of 2 wt% acetic acid and mixed with 10mL 1M CaCl2 
and 6mL 1M NaH2PO4 (Ca:P ratio = 1.67). The mixture was slowly dripped into a 
continuously stirred solution of 20% NaOH, 30% methanol, and 50% water (pH=13) to 
precipitate spherical chitosan-calcium phosphate microspheres. The C-nHA microspheres 
were kept in the precipitating solution for 24 hours to allow for the formation of nano-
crystalline hydroxyapatite. The C-nHA microspheres were then washed with deionized 
(DI) water until a neutral pH was achieved (pH 7-8). The C-nHA microspheres were 
frozen at 20°C for one hour and then transferred to a 2.5 liter Labconco freeze-dryer for 
48 hours to create lyophilized/porous C-nHA microspheres (Reves et al. 2009). 
2.2 Composite Scaffold Fabrication and Antibiotic Loading 
 
Each composite scaffold was made by mixing 600 mg of calcium sulfate (CaS, α-
hemihydrate, Wright Medical Technologies, Inc, Arlington, TN) and 80 mg lyophilized 
C-nHA microspheres with 0.24mL of DI water. The mixture was pressed into a mold to 
form a pellet that yielded a CaS to microsphere ratio of 88:12. This ratio was determined 
empirically for the size of the beads and the amount of CaS that was necessary to hold the 
scaffold together. C-nHA microspheres were pre-loaded via swelling (24 hrs at room 
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temperature) with 1.5 mL amikacin (10 mg/mL, MP Biomedical, LLC. Solon, OH) in DI 
water. Any remaining amikacin solution was removed and the C-nHA microspheres were 
washed once with 3mL of dIH2O in order to remove non-absorbed drug. The C-nHA 
microspheres were then mixed with CaS to form composite pellets. CaS was loaded with 
0.24 mL vancomycin hydrochloride (75.2mg/mL, Acros Organics, New Jersey) in DI 
water to yield 2 wt% of vancomycin per pellet. All pellets were dried overnight at room 
temperature to allow conversion to dihydrate form of CaS before use. The handling 
ability of the composite scaffold was tested after setting by manually pressing with a 
spatula and observing any crushing or breaking of the pellets. Two control groups were 
amikacin-loaded C-nHA microspheres (no CaS) and vancomycin-loaded CaS (no 
microspheres). Five test groups were evaluated: (1) Amikacin loaded C-nHA 
Microspheres incorporated into Vancomycin loaded Calcium sulfate (AMVC), (2) 
Amikacin C-nHA Microspheres alone (AM, control), (3) Vancomycin loaded Calcium 
sulfate without microspheres (VC, control), (4) Amikacin C-nHA Microspheres in 
Calcium sulfate without vancomycin (AMC) and (5) C-nHA Microspheres without 
amikacin in Vancomycin loaded Calcium sulfate (MVC). Vancomycin is commonly 
loaded in CaS and thus we loaded it into the CaS matrix components of our scaffold 
(Wichelhaus et al. 2001; Gitelis and Brebach 2002; Rauschmann et al. 2005; Jackson et 
al. 2009; Atilla et al. 2010; McPherson et al. 2013). We choose amikacin because it is 
effective against many types of bacteria such as Acinetobacter, Pseudomonas, and 
Enterobacter (Petersen et al. 2007). The C-nHA microspheres were loaded with amikacin 




2.3 Antibiotic Elution and Degradation 
 
Specimens (n=5 per group) were placed in individual wells of 48-well plates with 1.5 
mL PBS. Elution samples were taken at 1, 5, 12, 24 hrs and 2, 4, 7, 14, 20, 27, 34 and 42 
days. The PBS solution was completely refreshed after each elution time point. The 
collected elution samples were analyzed with a fluorescent polarization immunoassay 
(TDxFLx; Abbott Laboratories, Abbott Park, IL) (Jackson et al. 2009; Noel et al. 2010; 
Doty et al. 2014). Percent degradation and antibiotic release were calculated with Eqs. (1) 
and Eqs. (2) respectively. 
 
% !"#$%&%'()* =  !"#$#%& !"##!!"#$% !"##!"#$#%& !"## ∗ 100                               (1) 
 
 
% !"#$%$&#$' !"#$%"&' = 100− !!!!!!! ∗ 100                                (2) 
 
 
Where AL = Theoretical amount of loaded antibiotic and AC = Cumulative antibiotic 
release over 42 days. The theoretical amount of amikacin was determined by dissolving 
three sets of amikacin-loaded C-nHA microspheres (as mentioned above for scaffold 
fabrication) in 5mL of 1% acetic acid overnight. The dissolved solution was frozen at -
20C until analysis. The theoretical amount of vancomycin was calculated by the amount 
that was loaded into each scaffold.  
2.4 Inhibition of Growth and Bactericidal Assay  
 
Turbidity assays using S. aureus (Cowan I strain, ATCC 12598, Manassas, VA) and 
P. aeruginosa (ATCC 27317, Manassas, VA) in trypticase soy broth (TSB) were used to 
evaluate the inhibitory effectiveness of the released antibiotics (Noel et al. 2010; Doty et 
al. 2014). Techniques were adapted from the Clinical and Laboratory Standard Method 
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M07-A9 (CLSI 2012). Briefly, 200 µl composite scaffold eluates were added to sterile 
tubes containing 1.75 ml Trypticase soy broth (TSB) and inoculated with ~2x106 colony 
forming units (CFU) of S. aureus and P. aeruginosa respectively. Turbidity was 
determined spectrophotometrically (Spectronic Instruments, 20 Genesis) at OD530 after an 
overnight incubation at 37 °C and no-growth was indicated by OD <0.050. Bactericidal 
activity of samples was determined by plating dilutions of all samples that inhibited 
growth. Those samples that killed greater than 99.9% of the inoculum were considered 
bactericidal.  
2.5 Statistical Analysis 
 
Statistical analysis was performed with a Two-Way ANOVA on the release of 
vancomycin and amikacin from the composite scaffolds and on the activity of the eluates 
between groups and over time. Composite scaffold degradation was analyzed with One-
Way ANOVA. Post hoc analysis was carried out with Student-Newman-Keuls (SNK, 
P<0.05) when statistical differences were present. Turbidity and bactericidal statistical 
analysis performed with proportions test using contingency tables between the rate of 
inhibition of growth or bactericidal effect with a Fisher Exact test. 
3. Results 
  
3.1 Chitosan-nHA Microsphere Fabrication 
 
Chitosan-nHA microspheres were teardrop shaped, with a textured surface and a 
diameter of 1.40mm ± 0.23mm (Fig. 1). The composite scaffold measured approximately 
12.5mm diameter by 6.5mm high, with C-nHA microspheres uniformly distributed 




Fig. 1 Digital microscopy images (Keyence VHX-1000) of calcium sulfate powder 
(A), lyophilized chitosan-nHA microspheres (B), and composite pellet of chitosan-




3.2 Composite Scaffold Elution and Degradation  
 
Elution data showed that amikacin loaded C-nHA microspheres embedded in CaS 
with or without vancomycin (AMC and AMVC) exhibited a reduced burst and extended 
the release of amikacin compared to elution from C-nHA microspheres (AM) alone 
(P<0.001) (Fig 2). Statistical analyses indicated a significant interaction between time 
and groups (p< 0.001). Because of this interaction, subsequent analysis evaluated groups 
at each time point. There were statistically significant differences in the release of 
amikacin from AM, AMVC and AMC at every time point (p<0.05 except at 5hr, 
p=0.132). Amikacin release from AM was significantly greater than either AMC or 
AMVC (p<0.05) only at the 1hr time point. After 5hrs, the amikacin release from AM 
was significantly less than AMC and AMVC at every time point (p<0.05). This indicated 
a very rapid burst release from the C-nHA microspheres alone (AM) as compared to 
microspheres incorporated into the CaS matrix (AMVC/AMC). Initially, at 1hr, the 
amikacin release from AMC was higher than that of AMVC, but by 5hr there were no 
differences. From 12hr to14 days the AMVC released more amikacin than AMC but at 
Day 20 this shifted and AMC released more than AMVC throughout the rest of the study. 
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Amikacin recovery for all groups, regardless of the elution profile, was 41-42% and there 
were no statistical differences in percent recovery between the three groups, p = 0.582 




Fig. 2 Amikacin elution from scaffolds composed of chitosan-nHA microspheres 
embedded in calcium sulfate with or without vancomycin (AMC and AMVC) and 





The vancomycin release profile for all three groups showed an initial burst and 
subsequent decay over time (Fig. 3). Significant differences in the vancomycin release 
over time (p<0.05) were detected as well as significant interactions between time and 
group factors (p<0.05) indicating that the release of vancomycin was dependent on both 
time and scaffold composition. Further analysis at each time point revealed that there 
were statistical differences in vancomycin release between groups at all time points 
(p<0.05) except for 1hr where no statistical differences were reported (p=0.053). The 
vancomycin release from VC was notably high through day 2, and then dropped rapidly 
	 21	
exhibiting the statistically lowest levels of release for the rest of the study. Vancomycin 
release from MVC remained high through day 4, and then, similar to the VC, exhibited a 
drop in release, but the drop was less dramatic, and the levels of release remained 
statistically higher than VC after day 4. AMVC followed a different release pattern, with 
a statistically lower release compared to the other groups from 12hr through day 2 and a 
statistically higher release from day 4 to 42 suggesting a reduction in initial burst with a 
concomitant extension of vancomycin release. Vancomycin recovery from the scaffolds 




Fig. 3 Vancomycin elution from scaffolds composed of chitosan-nHA microspheres 
embedded in calcium sulfate with or without amikacin (MVC and AMVC) and 





Pellets exhibited an average change in mass of 47 ± 3% after six weeks and no 
statistical differences were noted, p= 0.064 (Table 1).  
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Table 1 Antibiotic recovery and change in mass of composite scaffolds over 6 weeks 
(n=5).  
Group % Amikacin Recovery 
% Vancomycin 
Recovery % Degradation 
AMVC 41.35 ± 1.91 102.42 ± 2.33 47.8 ± 2.3 
VC na 102.00 ± 1.44 46.5 ± 1.5 
AMC 41.04 ± 1.50 na 47.1 ± 3.4 
MVC na 98.72 ± 4.20 45.1 ± 3.5 
AM 42.45 ± 2.94 na nd 
na – not applicable because drug not in scaffold. nd – not determined, degradation was 




3.3 Inhibition of Growth and Bactericidal Assay 
  
The turbidity assays showed that the antibiotics eluted from AMVC inhibited S. 
aureus growth for 34 days and was bactericidal for 27days (Table 2). Groups VC and 
MVC were effective in inhibiting and killing S. aureus for 14 and 27 days respectively. 
Group AMVC abated P. aeruginosa for 24 hrs but was bactericidal for only 1 hr. Groups 
AM and AMC showed inhibition of P. aeruginosa through 24hrs and bacterial killing for 



















Table 2 Bacteriostatic and bactericidal activity of eluates containing vancomycin against 
S. aureus, and amikacin against P. aeruginosa (n=5). (-) indicates no growth, (+) 
indicates growth, (--) indicates reduction in the number of surviving CFU from the 
inoculum by 99.9% (killing), (++) indicates CFU growth > 0.01% of inoculum (no 
killing) and (--/++) partial killing in replicate samples due to slight variations in drug 
release at levels near the MIC. Symbol (*) denotes a statistical difference in proportion 







 In this study we evaluated in vitro a composite bone graft substitute for the dual 
delivery of vancomycin and amikacin to address the problem of treating polymicrobial 
orthopedic infections. Amikacin was absorbed into the C-nHA microspheres (36mg/g 
microsphere), and combined with the vancomycin-loaded CaS component (2wt% of CaS) 
without affecting the handling properties of the scaffold after setting, unlike some studies 
that report changes in crushability and setability with quinolone antibiotics or daptomycin 
(Mousset et al. 1995; Richelsoph et al. 2007). These two antibiotics were used to create a 
broad-spectrum antibiotic effect against both P. aeruginosa, and S. aureus, two bacteria 
 
S. aureus P. aeruginosa 
 
Bacteriostatic Bactericidal Bacteriostatic Bactericidal 
 
VC MVC AMVC VC MVC AMVC AM AMC AMVC AM AMC AMVC 
1hr - - - -- -- -- - - - -- -- -- 
5hr - - - -- -- -- - - - -- -- / ++ --/++ 
12hr - - - -- -- -- - - - ++ ++ ++ 
24hr - - - -- -- -- - - - ++ ++ ++ 
2d - - - -- -- -- + + + ++ ++ ++ 
4d - - - -- -- -- + + + ++ ++ ++ 
7d - - - -- -- -- + + + ++ ++ ++ 
14d - - - -- -- -- + + + ++ ++ ++ 
20d + - * - * ++ -- * -- * + + + ++ ++ ++ 
27d + - * - * ++ -- * -- * + + + ++ ++ ++ 
34d + + - * ++ ++ --/++ + + + ++ ++ ++ 
42d + + + ++ ++ ++ + + + ++ ++ ++ 
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commonly found in orthopaedic wounds (Hatzenbuehler and Pulling 2011; Hogan et al. 
2013). This study demonstrates that the use of the C-nHA microspheres and dual-
antibiotic loading reduced the in vitro burst release and extended the elution of both 
antibiotics compared to CaS or C-nHA microspheres alone. All scaffolds, regardless of 
composition, were less effective in inhibiting and killing P. aeruginosa than S. aureus. In 
bone scaffolds that incorporated C-nHA microspheres and vancomycin, the bacterial 
inhibition and killing of S. aureus was improved by 50-60% as compared to the 
vancomycin-loaded calcium sulfate group. In the presence of both antibiotics, the 
inhibition of S. aureus was further extended 20% due to an extended release and positive 
interaction between amikacin and vancomycin (Gentry 1997). The most effective 
antibacterial results reported for S. aureus were expected because the elution values of 
vancomycin containing scaffolds were 100-1000x above the breakpoint MIC (1µg/mL) 
for S. aureus for 7 days, whereas the highest elution value for amikacin was 55-130x 
above the breakpoint MIC (4µg/mL) for P. aeruginosa at 1hr (Jackson et al. 2009; Noel 
et al. 2010).  
Even though the vancomycin release for AMC was lower in the initial time points than 
the other groups, there was an extended elution that allowed the composite to remain 
active against S. aureus for the greatest amount of time and within the recommended 4-6 
weeks period for antibiotic treatment of orthopaedic wounds (Lew and Waldvogel 1997; 
Lazzarini et al. 2004; Nair et al. 2011). After 7 days, 96% of vancomycin was recovered 
from eluates for the AMVC and VCM composites compared to the same recovery after 
only 2 days for VC scaffolds, which shows the significant elution extension in the 
presence of C-nHA microspheres. One possible mechanism for the extended release is 
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that vancomycin was absorbed into and retained by the exterior surface of the porous C-
nHA microspheres during preparation. The large vancomycin molecules could have 
become entangled in the C-nHA microspheres and further delayed the antibiotic release. 
The bacterial inhibition we report for our dual-loaded scaffold containing C-nHA 
microspheres is 33 days longer than the 18-24 hour inhibition against several types of S. 
aureus (including MRSA) and S. intermedius reported by Atilla et al. for dual-loaded 
amikacin and vancomycin CaS beads (Atilla et al. 2010). Additionally, Howlin et al. 
reported no benefit in dual-loaded vancomycin-tobramycin CaS beads over single-loaded 
vancomycin CaS beads in zone of inhibition (ZOI) tests against MRSA (Howlin et al. 
2015). Even though vancomycin recovery from the dual-loaded scaffold at day 34 was 
102 ± 2%, there remained high enough concentration to inhibit S. aureus at this time 
point. This indicates that the CaS and C-nHA microspheres did not affect the activity of 
eluted antibiotics. The high recovery of vancomycin for all groups not only contributes to 
the extended antibiotic activity but also leads to less risk of bacterial resistance from 
long-term low-level elution.  
The amikacin release also followed a burst release pattern similar to other studies that 
report drug release from chitosan microspheres (Sinha et al. 2004; Aranaz et al. 2009; 
Reves et al. 2009). The delayed burst effect from groups containing C-nHA embedded in 
CaS, may be due to the physical barrier of calcium sulfate slowing elution or possible 
interactions with the matrix. Therefore, it is understandable that the amikacin recovery 
from AM is ~40% at 2 days compared to groups with C-nHA microspheres, where the 
recovery is ~40% after 14 days. A similar elution delay was noted in Doty et al. where a 
CaS matrix acted as a physical barrier and caused a one-day delay in rhBMP-2 elution 
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(Doty et al. 2014). While the amikacin elution fell below the MIC on days 7 and 27 for 
groups AM and AMVC respectively, the release for AMC was detectable throughout the 
42-day time course, suggesting that amikacin was still entrapped within the matrix and 
being slowly released. Although the eluted amikacin concentrations were 3-17 fold 
higher than MIC levels at 24hrs, the reduced efficacy of bacterial inhibition and killing 
compared to the measured concentrations may indicate that the drug is reacting with 
matrix components and either being inactivated or possibly forming a salt. Atilla et al. 
reported possible inactivation of amikacin when in lower pH environment, as may occur 
at the micro level with degrading CaS (Walsh et al. 2003; Atilla et al. 2010). Thus, the 
amikacin activity in the composite scaffolds may have been compromised and the activity 
reduced. Overall, our amikacin release was extended 2.6-4 times longer than what Atilla 
et al. reported for a dual amikacin-vancomycin-loaded plain CaS scaffold, indicating a 
benefit of slowed and extended release using C-nHA microspheres with CaS matrix 
(Atilla et al. 2010). Although Atilla et al. tested different strains of bacteria; they also 
reported short antimicrobial activity times of eluates, 18-24hr for scaffolds containing 
both antibiotics, possibly due to amikacin inactivation in a CaS environment (Atilla et al. 
2010). Future studies would require investigation into increasing the amikacin 
concentration, improving the loading efficiency and/or choosing another non-pH affected 
antibiotic in order to achieve a longer bacterial inhibition period. 
A look into the antibiotic loading of CaS and C-nHA microspheres reveals information 
about the elution potential. Vancomycin was loaded at 2 wt%, which is an effective “low 
dose” for premixed cements (Clyburn and Cui 2007). Although we achieved ~5 times 
higher amikacin loading than Reves et al. (~6.5mg/g chitosan) (Reves et al. 2009) our 
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amikacin loading yielded only 0.42 wt% pellet (36.7 mg/g chitosan), a much smaller 
amount compared to the vancomycin loading. Thus, it is understandable that the 
vancomycin eluates were able to sustain a longer activity against bacteria in vitro than the 
amikacin eluates. Inefficient loading, loss of amikacin upon loading (washing step), or 
inactivation could explain why the amikacin recovery was only ~41%. It is possible that 
increasing the surface area of the microsphere would allow more antibiotic absorption, 
thus using chitosan nanoparticles instead of microspheres could result in higher loading 
and subsequent release (Masri et al. 1995; Phillips et al. 2007; Romainor et al. 2014). The 
overall benefit of C-nHA microspheres in the CaS matrix loaded with two antibiotics is a 
slowed initial and extended elution rate for amikacin, despite the low antibiotic levels and 
the possible inactivation of amikacin in CaS. It is likely that by increasing antibiotic 
loading levels in the C-nHA microspheres or by using an alternative antibiotic to 
amikacin, the issues of reduced activity and short duration of elution could be minimized.  
This preliminary work is limited to in vitro assays and offers no direct correlation to 
clinical efficacy.  However, it does provide valuable foundational information about the 
co-delivery of two antibiotics from a CaS based scaffold that can be used to further 
develop composite implant strategies. The antibacterial assays for vancomycin suggest 
that extended elution would occur in vivo. The interactions of antibiotics with bone 
scaffold materials is not well known, and although in this study a composite approach 
altered elution and antibiotic activity, the exact mechanisms by which these effects 
occurred is not well understood. Further work is needed to improve the efficiency of 
amikacin loading and elution to determine if residual drug is remaining in the scaffold. 
Evaluating the effects of combinations of antibiotics and calcium sulfate in solution as 
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well as antibiotic salts may help to determine reasons for the lack of antibiotic activity 
against microorganisms at inhibitory concentrations. Additionally, more pH stable 
antibiotics may be studied to replace amikacin in the C-nHA microspheres, or synthetic 
calcium sulfates could be used as they have less acidic degradation products as well as 
extended elution (Parker et al. 2011; McPherson et al. 2013). A long-range goal, not 
encompassed in this work, would be for the slower-degrading, C-nHA microspheres to 
provide an osteoconductive scaffold for tissue regeneration as the CaS is resorbed.  
5. Conclusion 
 
Our goal to deliver therapeutically active antibiotics for 4 weeks from our composite 
scaffold was exceeded for the vancomycin release only, with the composite scaffold 
containing both amikacin and vancomycin. The dual antibiotic loaded calcium sulfate-
chitosan-nHA microsphere composite scaffold was able to elute and sustain bacterial 
activity against S. aureus for 2.4 times longer than vancomycin loaded calcium sulfate 
scaffolds alone. The amikacin loaded into the chitosan-nHA microspheres did show a 
slightly extended elution when embedded in the calcium sulfate matrix compared to free 
chitosan-nHA microspheres, however, the amikacin may have been inactivated in the 
calcium sulfate scaffold as it was degrading. Together these results indicate that dual 
antibiotic delivery over an extended period in one scaffold is possible and favorable 
compared to single antibiotic delivery systems. Loading one antibiotic into each 
component of the scaffold helped to slow the elution of both agents. Modifications to 
improve elution of amikacin could make this dual delivery method advantageous for 
treatment of orthopaedic wounds with polymicrobial infection. Studies evaluating these 
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biomaterials in preclinical models of contaminated musculoskeletal trauma should follow 
to confirm potential clinical efficacy.  
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COMPOSITE CHITOSAN AND CALCIUM SULFATE SCAFFOLD FOR DUAL 







Worldwide, two million people require bone-grafting procedures every year to repair 
injuries from traumatic events or disease [1]. In the US alone, approximately 112,000 
device related infections occur every year [2]. Additionally, conflicts in Iraq and 
Afghanistan have led to more than 21,000 combat injuries, of which approximately 65% 
are orthopaedic related traumas [3]. Combat wounds are largely extremity injuries, with 
23-39% being fractures, the majority of which are open wounds [4,5]. The incidents of 
infection in open fractures from civilian or combat cases averages around 10-20% but can 
be as low or high as 0-60% depending on the location and type of fracture, typically 
increasing with wound severity [2,5–7]. Infections in these complex musculoskeletal 
injuries can lead to non-unions, multiple surgical procedures, loss of function, prolonged 
recovery times, causing a greater burden on the healthcare system [5,8]. A leading cause 
of nosocomial infections, Staphylococcus aureus (S. aureus), is one of many bacteria that 
pose a severe threat to wound healing especially when drug resistance is acquired [9,10]. 
Uncontrolled, such bacterial contaminations can lead to limb amputation and patient 
death [11,12]. Thus, there is an important need for a multi-functioning bone graft capable 
of delivering pharmaceutical agents to prevent infection, simulate healing, and provide a 
substrate for bone regeneration. 
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In traumatic fractures, the natural immune response and effectiveness of systemic 
antibiotics can be significantly reduced when the vasculature is severely compromised 
[13,14]. To combat this, high levels of systemic antibiotics are used so that therapeutic 
levels can reach the wound site, however, this can cause organ toxicity and antibiotic 
resistance [13,14]. The local delivery of antibiotics is an alternative strategy that has been 
proven to be effective in delivering therapeutic doses of antibiotics to infected wound 
sites without toxicity issues [8,15,16]. Polymethylmethacrylate (PMMA) is the gold 
standard for local antibiotic delivery in infected wounds, however, it is not degradable, 
requires a second surgery for removal and can release subtherapeutic levels of antibiotics 
that may lead to bacterial resistance and/or reinfection [2,8,13,17]. Biodegradable local 
delivery systems, such as calcium sulfate, also overcome the challenges of systemic 
delivery in wounds with compromised vasculature and do not require a second surgery 
for removal or have the associated bacterial resistance potential since they dissolve in 
vivo [2,14,17,18].  
Successful healing of large fractures also requires concurrent tissue and bone 
regeneration in addition to infection control [2,6]. Treatments that address infection and 
tissue regeneration typically include a growth factor such as rhBMP-2 and an antibiotic, 
such as gentamicin, vancomycin or tobramycin. In vitro studies investigating dual 
delivery of antibiotics and rhBMP-2 from a titanium substrate or degradable polymers 
demonstrated that alkaline phosphatases (ALP) production by bone cells was greater 
when exposed to eluates containing both antibiotic and rhBMP-2 as compared to just 
antibiotics [19–21]. These studies showed unique delivery methods for dual therapeutic 
agents, but could not be customized in the operating room since their materials are 
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prepared in advance [19–21]. Delivery systems that can be customized are advantageous 
because the physician can tailor the therapeutic agents for individual needs and more 
effectively treat the patient [9,22]. Additionally, very few dual delivery studies for the 
treatment of infected bone fractures have examined the therapeutic interactions of eluted 
agents. Glatt et al. and Strobel et al. showed that the dual delivery of rhBMP-2 and high 
levels of antibiotics (600-1000 µg/mL Tobramycin and 10% wt gentamicin respectively) 
reduce the ALP production of cells compared to controls and cells exposed to lower 
concentrations of antibiotic [23,24]. These studies show that interactions of dual 
delivered agents can reduce the overall efficacy of the system. Thus, in order to develop a 
clinically relevant bone graft that can be customized to the patient, research and selection 
of appropriate therapeutic agents must be investigated.  
The effectiveness of delivering both rhBMP-2 and an antibiotic has been evaluated 
in a rat model with a collagen sponge [23] and degradable block copolymer [8], calcium 
sulfate scaffolds [25] and polyurethane scaffolds [26]. Glatt et al. and Suzuki et al. 
showed significant bone healing in the presence of scaffolds loaded with rhBMP-2 and 
antibiotic compared to scaffolds with no therapeutic agents, however, the inability to 
maintain 3D space [23] and manufacturing pre-loaded scaffolds [8] limit the use of these 
scaffolds. Similarly, Wang et al. found that in vitro and in vivo cellular response to 
calcium sulfate scaffolds containing rhBMP-2 and vancomycin showed significant 
increases over scaffolds containing no factors or vancomycin alone [25]. However, 
supraphysiological doses of rhBMP-2, as used by Wang et al. still cause concern for 
researchers and physicians alike [27,28]. In the presence of infection, Guelcher et al. 
showed that scaffolds loaded with rhBMP-2 (2.5 µg) and vancomycin (340 µg) 
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significantly increased the amount of regenerated bone compared to scaffolds with 
rhBMP-2 only. Scaffolds loaded with supraphysiological levels (25 µg) of rhBMP-2 were 
able to regenerate bone regardless of vancomycin delivery [26]. While this study showed 
that dual delivery was able to reduce the need for higher growth factor dosing, Guelcher 
et al. also reported inconsistent scaffold degradation with some scaffolds inhibiting 
cellular ingrowth, a problem that would affect short and long term healing. Nevertheless, 
these studies demonstrate that the co-delivery of rhBMP-2 and certain antibiotics is 
possible and effective in regenerating bone compared to controls. However, the 
shortcomings of these systems continue to be a lack of information about the interactions 
of co-delivered agents, systems that are not customizable by the surgeon in the operating 
room, and the use of supraphysiological doses of growth factor to compensate for burst 
release kinetics and enzymatic degradation [23,29]. 
The aim of this study is to develop a degradable composite for the treatment of large, 
infected bone injuries based on: chitosan microspheres for delivery of rhBMP-2 and 
calcium sulfate (CS) bone cement for delivery of an antibiotic, vancomycin. Vancomycin 
is commonly used antibiotic for the treatment of Gram-positive bacteria including 
methicillin-resistant Staphylococcus aureus (MRSA). Chitosan microspheres were 
selected because they are biodegradable, biocompatible and show promise as a 
drug/growth factor delivery vehicle [30–33]. Surgical-grade CS is a FDA approved bone 
graft material, has a predictable and rapid (~2 months) resorption rate and encourages 
angiogenesis and osteogenesis as it dissolves [34,35]. In addition CS cements have been 
used as a treatment for osteomyelitis since they sustain the release of antibiotics for 
several weeks [8,36]. In our approach, the microspheres loaded with rhBMP-2 (at low 
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concentrations) will be embedded in CS. The CS will act as a physical barrier to delay, 
slow and prolong growth factor release from embedded microspheres. The CS will act as 
a substrate to support bone healing and at the same time it will serve as a local delivery 
vehicle for vancomycin to treat/prevent infections in a wound site. The goals of this study 
are to develop a composite system that will be easily sterilizable, affordable, and able to 
be prepared in the operating room and can release antibiotics for 2-4 weeks for the 
prevention/elimination of bacterial infections as well as provide a delayed but sustained 
release of BMP. In this study we will evaluate the set time, drug release profiles, 
antimicrobial and cytocompatible properties of the composite graft as well as the in vitro 
effect of vancomycin on rhBMP-2 activity.   
Materials and Methods 
Chitosan-Calcium Phosphate Microsphere Fabrication  
A co-precipitation method as previously described was used for the fabrication of the 
chitosan/calcium phosphate composite microspheres [32]. Briefly a 3.57 wt% chitosan 
(80% DDA, 260 kDa, Primex EHF, Siglufjordur, Iceland) in 2 wt% acetic acid solution 
containing 0.1 M CaCl2, 0.1 M NaH2PO4, was dripped into a 20% NaOH, 30% methanol, 
50% deionized (dI) water (pH=13) solution to precipitate spherical microspheres. After 
24 hours in precipitating base solution to form crystalline hydroxyapatite, the 
microspheres were washed with dIH2O to pH 7-8, frozen for 2 hours at -80oC and 
lyophilized (Labconco FreeZone 2.5). The final microspheres were sterilized with 




Pharmaceutical Loading and Composite Scaffold Fabrication  
The composite scaffold was comprised of 100 mg microspheres and 0.6g CS 
(Calcium Sulfate, α-hemihydrate, Wright Medical Technologies, Inc, Arlington, TN). 
Prior to combining the two components, the microspheres were loaded with either 33.3 
µg /mL rhBMP-2 (PeproTech, Rocky Hill, NJ) or 6.66 mg/mL vancomycin 
hydrochloride (MP Biomedical, Solon, OH) at room temperature (RT) for 15 minutes 
(Table 1). The composite graft was made by mixing 0.6 g CS and 180 µL vancomycin 
[86.7mg/mL] in a 13mm diameter x 7mm high polyethylene mold with microspheres and 
thoroughly mixed for 40 stirs in 20 seconds. The mold was tapped 20 times on the bench 
to remove air bubbles and allowed to set.  
 
Table 1: Key to composites and relative loading of vancomycin and rhBMP-2. 
Nomenclature: CS2/CS0, represents the wt% of vancomycin in the CS component and 
symbols in parentheses represent the mass ratio of B (rhBMP-2) or V (vancomycin) 
loaded into the microspheres. 
Group Vancomycin 










within CS  
rhBMP-2 (µg) in 
composite 
microspheres 





Vancomycin (mg) in 
composite 
microspheres based 





CS2(B0V4) 15.6 0:4 0 1 
CS2(B4V0) 15.6 4:0 5 0 
CS2(B1V3) 15.6 1:3 1.25 0.75 
CS2(B2V2) 15.6 2:2 2.5 0.5 
CS2(B3V1) 15.6 3:1 3.75 0.25 
CS2(B0V0)* 15.6 -- 0 0 
CS0(B0V0)* 0 -- 0 0 






Viacat hardness test  
 To determine if the addition of microspheres and pharmaceutical agents affected 
the set time of the material, a set test based on the ASTM Standard C472.26 (Standard 
Test Methods for Physical Testing of Gypsum, Gypsum Plasters and Gypsum Concrete, 
ASTM, Inc., PA, USA), was performed. The Viacat needle (1mm diameter) was allowed 
to penetrate the sample and the height was recorded. The test was repeated until the 
needle penetrated less than half the original height, at which time the material was 
considered set. Only the groups with the highest concentrations of therapeutic agents 
were tested against control scaffolds containing no therapeutic agents (CS2(B0V4), 
CS2(B4V0), CS2(B0V0), and CS0(B0V0), n=3) since the set time will be influenced 
most at the highest drug concentrations.  
Composite Scaffold Elution and Degradation 
To evaluate the release of rhBMP-2 and vancomycin, scaffolds (n=5/group) were 
placed in 3 mL of McCoy’s 5A medium +10% Fetal Bovine Serum (FBS) and placed in 
an incubator at 37oC. At 1, 2, 3, 5, 7, 9, 11, 14, 18, 21, 28, 35 and 42 days, the medium 
was completely removed, replaced with fresh medium and returned to the incubator. 
Eluates were stored at -20oC until analyzed. rhBMP-2 and vancomycin release were 
measured with an Enzyme-Linked Immunosorbent Assay (ELISA) (PeproTech, Rocky 
Hill, NJ) and Fluorescence Polarization Immunoassay (FPIA) (TDxFLx, Abbott 
Laboratories) respectively. For the degradation study of the composite scaffolds, mass 




Bacteriostatic and Bactericidal Assay Analysis  
To test antibacterial activity of released vancomycin, a method adapted from the 
Clinical and Laboratory Standard Method M07-A9 was performed [37]. Briefly, tubes 
containing 1.75 mL of trypticase soy broth were inoculated with 50 µL of 2x106 colony 
forming units (CFU) of S. aureus (Cowan I strain, ATCC 12598, Manassas, VA), and 
200 µL of composite scaffold eluates.  After incubating overnight at 37oC, the turbidity 
was determined spectrophotometrically (Spectronic Instruments, 20 Genesis) at OD530, 
and no-growth was indicated by OD <0.050. To determine if the released vancomycin 
was not only bacteriostatic but also bactericidal, the samples that exhibited no bacterial 
growth were plated (50 µL) onto TSB plates and incubated overnight at 37oC and viable 
CFU were counted on the plates. Eluates were considered bactericidal if there was a 
99.9% reduction in CFU of the inoculum.  
Determination of rhBMP-2 Activity in Eluates 
W-20-17 cells (ATCC CRL-2623, Manassas, VA) were seeded at 3x104cells/cm2 
with DMEM High Glucose in 96 well plates for 24 hours at 37oC and 5% CO2. Cells 
were washed three times with 200 µL PBS and then exposed to 200 µL of the collected 
eluates for 24 hours at 37oC and 5% CO2. Viability was determined with CellTiter 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) and rhBMP-2 
activity was determined with an alkaline phosphatase (ALP) assay. ALP assay was 
conducted by lysing cells in 80 µL RNA free H2O with two freeze thaws at -80oC, 
followed by the addition of 20 µL 0.5M alkaline buffer (Sigma-Aldrich, St. Louis, MO), 
100 µL 5mM Phosphatase substrate (Sigma-Aldrich, St. Louis, MO) and 50 minutes 
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incubation at 37oC. 100 µL of 0.3M NaOH stop solution was then added and the plate 
was read spectrophotometrically (Molecular Devices, SpectraMAX Plus) at 405nm. 
Detection of rhBMP-2 Elution from Microspheres 
To help determine the role of CS as a barrier for rhBMP-2 release, the elution of 
rhBMP-2 was evaluated from microspheres alone. Microspheres (100 mg) were loaded as 
previously described with 5 µg rhBMP-2 and eluted for 6 weeks in 3 mL of McCoy’s 5A 
+ 1% Bovine Serum Albumin (BSA) to reduce non-specific adsorption of rhBMP-2. 
Additionally, to check the effects of sampling intervals, two groups of microspheres were 
tested; eluates were collected daily for six weeks in one group and eluates were collected 
at intervals to match those used in the six-week elution test of composites for the second 
group. Eluates were completely refreshed at every collection and stored at -20oC until 
analysis.  
Determination of rhBMP-2 Activity in the Presence of Vancomycin 
To investigate the possible interactions of rhBMP-2 and vancomycin without any 
interference from the calcium sulfate matrix, W20-17 cells were used to perform an in 
vitro assessment. Cells were exposed to 200 µL of a dual agent solution made in DMEM 
High Glucose Medium of rhBMP-2 (0,10,50,100,500,1000 ng/mL) and vancomycin (0, 
12.5, 450, 1800, 3600 µg/mL). After 24 hours, cellular viability and activity were 
determined spectrophotometrically.  
Statistical Analysis 
Statistical analysis was performed with a Two-Way ANOVA on the release of 
vancomycin and rhBMP-2 from the composite scaffolds over time and on the activity of 
the eluates and dual agent solutions in culture.  Composite scaffold setting time and 
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degradation was analyzed with One-Way ANOVA. When statistical differences were 
detected, post hoc analysis was carried out with Student –Newman-Keuls (SNK, P<0.05).  
Results 
Chitosan-Calcium Phosphate Microsphere –Calcium Sulfate Composite Scaffold 
Fabrication  
Chitosan-calcium phosphate microspheres were precipitated and lyophilized (Fig. 
1a). Average size of the microspheres was 1.40mm ± 0.23mm, the shape was teardrop 
and the surface had a textured appearance (Fig. 1a). Composite scaffolds had uniformly 
distributed microspheres and maintained their shape after removal from the mold (Fig. 




Fig. 1 Lyophilized chitosan-calcium phosphate microspheres (a), calcium sulfate powder 
(b), and composite pellet of microspheres incorporated into calcium sulfate(c), close up 




Viacat Hardness Test  
The Viacat test demonstrated cement set times between 18-36 minutes for the groups 
tested. The composite with rhBMP-2 loaded microspheres took statistically longer to set 




Table 2: Composite scaffold set times in minutes ± mean standard deviation (std). 
Symbols (*) indicate statistical difference from symbol (#) at p<0.05.  
Group CS0 CS2 CS2(B0V0) CS2(B0V4) CS2(B4V0) 




Composite Scaffold Elution 
 
The release profile of vancomycin from composite scaffolds showed a burst release 
over the first two days followed by continuous low-level release (Fig. 2). The percent of 
vancomycin recovered from the scaffolds was 99.32 ± 2.37%. Statistical differences were 
found over time (p< 0.001) and between groups (p< 0.007) and there was a significant 
interaction between time and groups (p< 0.001), indicating that the release is dependent 
not only on time but also on the composition of the scaffold. Subsequent analysis 
evaluated groups at each time points and post hoc analyses revealed that there were 
statistical differences in vancomycin release between some groups on days 1, 2 and 3. 
However, differences were not consistent between groups over these three measurement 
periods (data not shown) and are most likely due to slight variations in the composition of 
the hand made samples. After day 3 no statistical differences were observed within a time 
point for vancomycin release from any of the groups. Overtime, the vancomycin 
exhibited a burst release with the highest levels being released on day 1 and decreasing 
over time. By day 18, there was no statistical difference in vancomycin release over the 





Fig. 2 Vancomycin elution from composite scaffold (n=5). Groups with similar symbols 




The results of the analysis of rhBMP-2 release from the composite scaffolds are 
shown in Fig. 3. Significant differences in rhBMP-2 released over time and between 
groups (p<0.001) were detected as well as significant interactions between time and 
group factors (p<0.001) which indicates that the release is depended on time and graft 
composition. The scaffolds showed a dose dependent release for the scaffolds loaded 
with the greatest amount of rhBMP-2 (CS2(B4V0); 5 µg rhBMP-2/pellet) showing the 
greatest release at all time points followed by each group in order of amount of rhBMP-2 
loading. Despite the interactions, a clear trend can be seen in the data of a delayed and 









The composite scaffolds lost approximately 40% mass over six weeks (Table 3), 
with statistical differences between groups CS0(B0V0), CS2(B2V2) and CS2(B3V1) 
(p=0.014 and p=0.029 respectively). 
 
Table 3: Recovery and change in mass of composite scaffolds over 6 weeks (n=5). 










(g) ± std 
Average 
Ending Mass 
(g) ± std 
% 
Decrease 
CS2(B0V4) na 102.18 0.950 ± 0.010 0.567 ± 0.014 40.2 ± 0.01 
CS2(B4V0) 1.17 96.19 0.933 ± 0.017 0.560 ± 0.013 40.0 ± 0.02 
CS2(B3V1) 1.07 98.96 0.938 ± 0.016# 0.553 ± 0.021 41.1 ± 0.03 
CS2(B2V2) 1.0 101.75 0.920 ± 0.021* 0.564 ± 0.011 38.7 ± 0.01 
CS2(B1V3) 0.98 97.27 0.925 ± 0.018 0.564 ± 0.008 39.0 ± 0.01 
CS2(B0V0) na 99.61 0.942 ± 0.021 0.564 ± 0.005 40.1 ± 0.01 




Elution of released rhBMP-2 from chitosan microspheres 
Cumulative release of rhBMP-2 from chitosan microspheres sampled every day was 
240.98 ± 14.34 ng/mL (20.46% recovery) and 151.86 ± 37.61 ng/mL (14.18% recovery) 
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from the interval sampled group (data not shown). Statistical analyses showed that there 
were no differences in levels released between groups for days 1 through 7 (p>0.05). 
However, after day 9, the daily sampled group showed consistently greater levels of 
release as compared to the interval group (p<0.05). The rhBMP-2 release from 
microspheres exhibited a burst release on day 1 followed by a slow decrease and a steady 
state release around 2.5 ng/mL after day 11.  
A comparison of the rhBMP-2 released from the composite graft CS2(B4V0) and the 
microspheres alone can be seen in Fig. 4. Through day 11, the difference between the 
composite graft and the microsphere rhBMP-2 elution was 87-99%. After day 11, the 
differences range from 22-62%, with 22% occurring on day 35/36. However, it should be 
noted that day 36 for the microsphere group may be reduced because day 35 sample was 
lost, and was collected on day 36, thus this is an artificially reduced measurement. 
 
 
Fig. 4 Elution comparison of rhBMP-2 from composite graft and microspheres (n=5). 
Elution day 35 was lost during collection of the microsphere samples, thus day 36 was 
collected instead  
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Bacteriostatic and Bactericidal Assays with Composite Scaffold Eluates 
The ability of eluted samples to inhibit the growth and kill the model bacterium, S. 
aureus is shown in Tables 4 and 5 respectively. All groups with 2% vancomycin in the 
CS component showed both inhibition of bacterial growth indicated by (-) in Table 4 and 
bactericidal activity as indicated by a reduction of ≥ 99.9% of the inoculum of S. aureus 
through day 18 indicated by √ in Table 5. 
 
Table 4: Bacteriostatic activity of eluates containing vancomycin against S. aureus 
(n=5). (-) indicates no growth, (+) indicates growth and (±) indicates growth or no growth 
in replicate samples due to slight variations in drug release at levels near the MIC. All (+) 
groups were found to be statistically different from (- and ±) groups (p<0.05). 
 Days 
Group 1 2 3 5 7 8 11 14 18 21 28 35 42 
CS2(B0V4) - - - - - - - - - + + + + 
CS2(B4V0) - - - - - - - - - ± + + + 
CS2(B1V3) - - - - - - - - - ± + + + 
CS2(B2V2) - - - - - - - - - ± + + + 
CS2(B3V1) - - - - - - - - - ± + + + 
CS2(B0V0) - - - - - - - - - + + + + 
CS0(B0V0) + + + + + + + + + + + + + 
 
 
Table 5: Bactericidal activity of eluates containing vancomycin against S. 
aureus (n=5). (√) indicates that the eluates reduced the number of colony forming units of 
the inoculum by 99.9%. All (√) groups were found to be statistically different from (       ) 








Group 1 2 3 5 7 8 11 14 18 21 28 35 42 
CS2(B0V4) √ √ √ √ √ √ √ √ √        
CS2(B4V0) √ √ √ √ √ √ √ √ √ *       
CS2(B1V3) √ √ √ √ √ √ √ √ √ *       
CS2(B2V2) √ √ √ √ √ √ √ √ √ *       
CS2(B3V1) √ √ √ √ √ √ √ √ √ *       
CS2(B0V0) √ √ √ √ √ √ √ √ √        
CS0(B0V0)                           
* partial killing,  no killing     
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Activity of rhBMP-2 from Composite Scaffold Elution 
Difficulties arose when running this assay due to the high calcium and sulfate ion levels 
present in the eluates. W-20-17 cell were unable to survive in the presence of these 
eluates regardless of antibiotic or growth factor presence (data not shown). These cell 
culture difficulties with high calcium and sulfate ion levels have been reported in other 
studies [38]. 
Dual Agent Solution Viability and Activity 
Results of the effects of the dual agent solutions on cell viability are shown in Fig. 5 
and ALP expression in Fig. 6. There was only a slight, statistical difference in viability 
from cells exposed to vancomycin doses at the highest rhBMP-2 dose. For all other 
analyses, there were no statistical differences in viability of the cells based on rhBMP-2 
dose levels (P=0.586), or vancomycin dose levels (P>0.5), nor was there a significant 
interaction (P=0.613). The 1000 ng/mL rhBMP-2 dose level had a statistical difference in 
cellular viability. In this group, the viability of cells exposed to the 0 µg/mL vancomycin 
level were statistically greater than all other vancomycin containing solutions (P<0.019). 
There were no statistical differences in viability of the cells exposed to the other 
vancomycin containing solutions. Thus, reduced cell number may influence the data at 
1000 ng/mL rhBMP-2 on the ALP graph, however, the trend of reduced ALP with 
increased vancomycin concentrations is apparent by 50 ng/mL.  
Dual agent solutions, that contained vancomycin concentrations of 1800 µg/ml and 
above, did result in a suppression of ALP by the W-20-17 murine cells as compared to 
eluates with lower concentrations of vancomycin (Fig. 5). The inhibition of ALP 
expression was proportional to the amount of vancomycin in the dual agent solutions 
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with highest concentration of vancomycin tested (3600 µg/ml) showing more inhibition 
than (1800 µg/ml), whereas the lower levels did not show ALP inhibition. Significant 
differences between rhBMP-2 dose level (p< 0.001) and vancomycin dose level (p< 
0.001) were indicated as well as significant interaction between the two (p< 0.001). At 
concentrations of 100 -1000 ng/mL rhBMP-2, ALP production from cells exposed to 
1800 and 3600 µg/mL vancomycin was statistically different from that of cells exposed 
to 0 - 450 µg/mL vancomycin (p<0.001).  
 
 
Fig. 5 W-20-17 cell viability in the presence of rhBMP-2 and vancomycin (n=3). Letters 
indicate statistical differences within the 1000 ng/mL rhBMP-2 dosing group, as this was 
the only group that showed statistical differences. In the 1000 ng/mL rhBMP-2 level, the 
0 ng/mL vancomycin group had a spastically greater viability than the other groups (P < 







Fig. 6 ALP production by W-20-17 cells in response to varying levels of rhBMP-2 in the 
presence of vancomycin (n=3). Within each rhBMP-2 concentration level, bars with 





A degradable composite graft material, composed of chitosan microspheres (loaded 
with rhBMP-2 and/or vancomycin) embedded in CS bone cement (loaded with 
vancomycin) was investigated as a dual therapeutic delivery device for infection control 
and fracture healing in traumatic bone injuries. In this study, composite grafts and 
microspheres alone were evaluated to determine the elution profiles and activity of 
released therapeutic agents as well as, an investigation into the interactive effects of 
dually delivering a growth factor and antibiotic. Results showed that all scaffold 
compositions set in under 36 minutes, and the antibiotic elution exhibited a burst 
followed by an extended release that was able to kill S. aureus in vitro for 18 days. The 
rhBMP-2 delivery from the composite scaffold was delayed for one day and extended 
over 6 weeks. Additionally, it was observed that vancomycin at high levels (3600 and 
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1800 µg/mL) inhibited rhBMP-2 as indicated by ALP production from W-20-17 cells 
confirming the need for in vitro activity testing of dually delivered therapeutics. 
The vancomycin release shown in this work is similar to that of other studies, where 
there is an initial burst of antibiotic release followed by a therapeutically active and 
extended release [39–41]. All of our composite graft groups were able to release 
vancomycin that effectively inhibited growth of S. aureus for 2.5 weeks. It has been 
suggested that antibiotic release should last should last 4-6 weeks based the healing times 
for the reestablishment of vasculature in bone tissue [2,6,39,41]. While the release in this 
study was 1.5 weeks shy of this suggested timeframe, our dosing level of 2% is also 
lower than a common clinical dosing of 3.64% vancomycin [16,18]. We chose this lower 
dose to reduce potential interactions of vancomycin with rhBMP-2. Increasing the 
vancomycin loading could extend the therapeutically active release into the 4-6 week 
timeframe without much if any inhibition of rhBMP-2 due to the delay in growth factor 
release that we detected from the scaffold. Nevertheless, the composite showed nearly 
complete vancomycin recovery at 18 days (98.94 ± 2.68% recovery) and 42 days (99.32 
± 2.37% recovery) suggesting a low potential for contributing to bacterial resistance due 
to extended subtherapeutic levels. 
Due to the low elution of rhBMP-2 from the composite grafts (~1 ng/mL/time point 
for the highest loaded group CS2(B4V0)) it is suspected that the majority of the rhBMP-2 
loaded into the microspheres may have been retained by the calcium components of the 
graft. The affinity of rhBMP-2 for calcium phosphate materials has been previously noted 
in literature [29,42,43], and from the results of the microsphere elution where the rhBMP-
2 release was found to be on average 72% greater than the rhBMP-2 release from 
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composites we confirm our findings. Even though the rhBMP-2 elution from the 
composite was not enough to elicit a noticeable ALP increase in W-20-17 cells, a general 
trend of the rhBMP-2 release was found to be directly proportional to the loaded amount 
of growth factor. However, due to the variability in the amount of agents eluted from the 
composite scaffold, statistical differences were not consistent between groups at all 
evaluation time points. The elution profile from the microspheres was similar to that of 
Reves et al., where rhBMP-2 elution from lyophilized chitosan microspheres was 
sustained for 26 days [33]. Overall, affinity of rhBMP-2 for calcium materials may be a 
technique for localizing delivery to a specific area [38]. We hypothesize that in vivo, the 
calcium sulfate graft will dissolve releasing the bound growth factor at a prolonged 
higher dose, and further animal testing is needed to investigate this hypothesis. 
Additionally, daily and intermittent sampling methods were tested with rhBMP-2 elution 
from microspheres, and results found a 40% increase in detected rhBMP-2 in the daily 
sampled group compared to the intermittently sampled group. This measured decrease is 
most likely a result of rhBMP-2 denaturing over time, particularly over the larger interval 
times (4-7days) and may cause an underestimated amount of active rhBMP-2 released 
from scaffolds sampled intermittently [27,29,44]. Thus, future in vitro elution studies 
with rhBMP-2 should be sampled every day to avoid this reduction in activity.   
Despite the reported issues (fast resorption and lack of strength), calcium sulfate has 
been a successful device for bone regeneration and infection control [25,36]. There is 
further potential for calcium sulfate to be used in a combination device, as we 
demonstrated with chitosan microspheres due to the retention and delivery of rhBMP-2 
locally in a wound area. Calcium sulfate has been shown to exhibit surface dissolution of 
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ions into the surrounding medium [45]. In our study, this scaffold dissolution left 
noticeable precipitation in all of the elution samples and caused an ionic imbalance in our 
cellular studies [38]. Thus, there was reduced viability in cells containing eluates from 
the composite scaffolds compared to controls in growth medium only (p<0.05, data not 
shown). This is unfortunately a consequence of static tissue culture, however it is 
important to note that in vivo calcium sulfate is considered biocompatible due to the 
accelerated and successful regeneration of bone [36,46,47].  
It has been previously shown that high levels of antibiotics can cause cell death in 
vitro or tissue toxicity in vivo [48,49], thus, it is important to address the potential effects 
of the released antibiotic on the bioactivity of rhBMP-2 To do this dual agent solutions of 
rhBMP-2 and vancomycin were made in a range to cover the values measured from the 
elution study and values known to stimulate ALP expression in W-20-17 cells. The 
results showed that higher levels of vancomycin (1800-3600 µg/mL) interfere with 
rhBMP-2 stimulated osteogenesis observed by the reduction in ALP. Thus, interactive 
effects of therapeutic agents should be considered in dual delivery systems in order to 
provide the most effective doses and clinical outcomes. It should be noted that in vivo, 
the highest levels of vancomycin are typically released from scaffolds in the early time 
points when inhibitory effects on rhBMP-2 would be at a maximum. However, the lack 
of osteoprogenitor cells in the wound site at his stage is minimal so this initial inhibitory 
effect may not be critical, especially if the rhBMP-2 release is delayed [50–52].  
Tobramycin and rhBMP-2 were both evaluated in vitro and in vivo as a dual delivery 
system by Glatt et al. In a rat model, Glatt successfully showed healing with a collagen 
sponge delivery system carrying both agents, however, in vitro, they found a dose 
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dependent reduction in rhBMP-2 activity with increasing tobramycin concentrations, 
similar to our study [23]. Similarly, Wang et al. also showed significant bone 
regeneration in vivo (>14 days) for calcium sulfate composites loaded with vancomycin 
and rhBMP-2 compared to controls. However, Wang et al. did not report any inhibitory 
effects of the dual agents in vitro, probably because they did not have sufficient controls 
or time points to evaluate agent interactions [25]. While both studies were able to support 
the beneficial effects of rhBMP-2 in vivo only one evaluated the interactions the dually 
delivered agents. Thus, dual delivery systems are a viable option for efficient fracture 
healing in the presence of antibiotics and it remains important to determine the reactivity 
of the agents in order to achieve an appropriate dosing scheme and thus reduce the cost 
and improve the efficiency of healing.  
Conclusion 
In this study, we showed that the chitosan/calcium sulfate scaffold was able to 
deliver both an antibiotic and a growth factor in vitro over a clinically relevant time 
period. The model therapeutics used in this study, vancomycin and rhBMP-2, are 
representative of treatments that are necessary for simultaneously preventing infection, 
regenerating tissue and reducing healing complications in large bone defects. The 
extended antibiotic release exhibited in this work is important to eliminate and prevent 
infections that could interfere and delay healing in contaminated fracture wounds. 
Additionally, the ability of this graft material to extend the rhBMP-2 delivery is crucial to 
overcome the challenges of regenerating bone in large defects. The decreased cellular 
response to rhBMP-2 in the presence of high levels of vancomycin reinforced the 
necessity to evaluate drug interactions in dual delivery systems in order to achieve 
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optimal therapeutic outcomes. In summary large fracture wounds, where the vasculature 
is often compromised, require multiple factors to aid in tissue repair and infection 
control. Our research reports the effective dual delivery from a degradable bone scaffold 
while supporting the need to investigate the potential interactions of co-administered 
pharmaceutical agents. 
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EVALUATION OF A CALCIUM SULFATE-CHITOSAN FIBER-MESH 







A recent study estimated that over $5 billion dollars per year will be spent in the US 
alone for treating severe orthopaedic traumas including bone excisions, grafting and 
fracture repair 1. Orthopaedic traumas may become infected with a variety of pathogenic 
bacteria at the time of injury, while in the hospital, or afterwards during healing. Wound 
healing in patients with infected orthopaedic fractures is complicated and continues to 
plague the medical community. Infections have been reported in as many as 60% of 
battlefield open fracture wounds and 65% of civilian open fractures 2,3. Infections at the 
site of orthopaedic traumas can lead to multiple surgeries, extended antibiotic treatment, 
limb amputation, and even patient death 3–5. Treatment of infected bone is particularly 
challenging due to compromised vasculature, especially in devastating traumatic injuries 
with substantial tissue damage where the immune response and systemic antibiotic 
treatment are cut off from the wound site 6. Thus, there is a critical need for therapies that 
fight/prevent infection and stimulate bone regeneration to aid in healing of large, infected 
orthopaedic fractures. Ideal dual delivery systems for treating infected fractures should 
have the following key characteristics: degrades at the same rate as healing, 
controls/sustains the release of growth factors, extends the release of antibiotics, is 
customizable for individualized care and maintains mechanical integrity to support 
regeneration in a critical size defect 7–10.            
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To address this challenge several studies have investigated the dual delivery of a 
growth factor, BMP-2, and antibiotics from bone grafts and coatings 5,11–18. These studies 
investigated, BMP-2 because of its potent osteoinductive properties 19–22, in combination 
with different antibiotics such as vancomycin, teicoplanin, and gentamicin 5,11–18. Wang 
et al. investigated BMP-2 and vancomycin loaded into CS pellets and found that BMP-2 
was active for 29 days in vitro and that rabbit tibial defects had significantly more new 
bone growth after 28 days in the presence of scaffolds loaded with both factors over 
controls. While Wang et al. demonstrated that both therapeutic agents could be extended 
over several weeks, the activity of the antibiotics was not tested, and the use of 
supraphysiological doses (50 μg – 60 mg) of BMP-2 increases the cost of treatment and 
raises concerns about safety and negative side effects such as ectopic bone formation 
21,23–25.  
The co-delivery of low-dose BMP-2 and vancomycin from a composite pHEMA-
nHA scaffold was evaluated in vitro and in vivo 14,15. The BMP-2 release in vitro from 
these scaffolds containing 300 ng BMP-2 and 4.8% vancomycin was relatively fast with 
95% eluted over 48hrs 14. However, full bridging in femoral rat defect after 12 weeks was 
found with a pHEMA-nHA scaffold with 3 µg BMP-2 and 4.8% vancomycin 15. While Li 
et al. reported a burst and 2 week extended elution of vancomycin from the dual loaded 
pHEMA-nHA scaffold, activity against E.coli was only established for 48 hr, and activity 
was not tested in vivo by Skelly et al. 14,15. Thus, even though low levels of BMP-2 were 
shown to repair bone in vivo, the effectiveness of antibiotics over an extended period was 
not evaluated, nor could these scaffolds be easily customizable since they require several 
days to prepare. Guelcher et al. reported modest and low burst levels of BMP-2 and 
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vancomycin from a PUR scaffold after 5 days followed by an extended 21-day release in 
vitro. They also evaluated the dual-delivery graft in an infected femoral rat defect and 
found that PUR scaffolds loaded with either 2.5 µg or 25 µg BMP-2 and vancomycin had 
more bone growth than either a collagen control or non-antibiotic loaded group after 8 
weeks 18. Guelcher et al. was able to show extended therapeutic delivery and excellent 
translation in an animal model. However a shortcoming of their work was inconsistent 
scaffold degradation, which could prevent tissue regeneration. The above studies show 
that the co-delivery of BMP-2 and vancomycin can be successful in regenerating tissue 
and fighting infection, but continue to have shortcomings in one or more areas such as 
controlled and sustained drug release, degradation rate equal to tissue regeneration and 
customizability.  
We have investigated a composite scaffold made from a calcium sulfate matrix 
reinforced with a chitosan fiber-mesh to determine if it will meet criteria for effective 
dual delivery of a growth factor and antibiotic from a bone scaffold. CS is an approved 
FDA device, that degrades at a rate similar to bone regeneration, is biocompatible, and 
can deliver clinically relevant doses of antibiotics (such as cefazolin, vancomycin, 
gentamycin) in vivo for several weeks 26–33. Due to the favorable cellular and tissue 
response in vitro and in vivo, chitosan, has been widely studied for biomaterial 
application and has been shown to be a good carrier for many therapeutic agents 34–36. 
Previous work in our lab has reported >90% retention of BMP-2 from CS/chitosan 
scaffolds over 6 weeks. In order to increase the BMP-2 elution while maintaining the 
favorable elution kinetics (reduced burst and extension) a chitosan fiber-mesh was 
investigated. It has been reported in the literature that resorbable fibers create 
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interconnected pores throughout calcium phosphate cements (CPC) as they degrade 37–40. 
These interconnected channels extend into the interior of the ceramic matrix and may 
allow for diffusion of growth factor from the interior of the scaffold and enhanced tissue 
ingrowth 37,38,40,41. Additionally, research has shown that chitosan fiber-reinforced 
scaffolds were able to increase compressive and flexural strengths with calcium 
phosphate and collagen based scaffolds 42–44.  Increased mechanical strengths would be 
beneficial for load bearing applications, to provide a 3D platform for cellular attachment, 
and to facilitate new bone growth.  
Additionally, the composite graft may be prepared on the bench as a point-of-care 
device to enable the surgeon to customize it with desired antibiotics and growth factors. 
The chitosan fiber-mesh may be pre-loaded with physician selected growth factors or 
other therapeutic agents via swelling. An antibiotic or other therapeutic agent may be 
added to CS and fiber-mesh individually prior to combining into a single composite. The 
growth factor rhBMP-2 will be used as a model growth factor and loaded into the 
chitosan fiber-mesh component. The antibiotic, vancomycin, will be used as the model 
antibiotic and mixed into the CS component. Chitosan lactate will also be investigated as 
a mechanism to improve binding of the fiber-mesh within the CS matrix. We 
hypothesized that 1) the eluted antibiotics will be active against bacteria for 4-6 weeks, 2) 
incorporation of rhBMP-2-loaded chitosan mesh into the CS will delay and extend the 
growth factor release, 3) chitosan lactate incorporation will improve the binding between 
chitosan mesh and CS matrix and 4) the addition of chitosan fiber-mesh will improve the 
mechanical properties of the scaffold. 
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Materials and Methods 
Chitosan Fiber-Mesh Fabrication 
Chitosan fiber-meshes were fabricated with a co-precipitation wet-spinning method 
based on a bead fabrication method45. Briefly, a solution of 3% chitosan (80% DDA, 260 
kDa, Primex EHF, Siglufjordur, Iceland) was prepared in 2 wt% acetic acid solution. 
After 24 hours, the solution was strained through a fine mesh to remove any undissolved 
chitosan flakes and loaded into a syringe with a 21-gauge needle. The syringe was loaded 
into a pump and extruded continuously (>0.8ml/min) into a solution of 20% NaOH, 30% 
methanol, and 50% deionized (dI) water (pH=13).  The fibers were extruded into the base 
as it rocked on a Belly Dancer shaker at 2 RPM. After wet spinning, the mesh was 
washed with deionized water (dIH2O) until a neutral pH was achieved (pH 7-8). Using a 
8mm punch, meshes were cut, air dried, and sterilized with ethylene oxide gas.  
Scaffold Preparation and Therapeutic Agent Loading 
Composite scaffolds were made with 0.53g α-hemihydrate Calcium Sulfate (CS) 
(Wright Medical Technologies, Inc, Arlington, TN) and either 4% or 7% chitosan fiber-
mesh (by wt to CS powder). Chitosan lactate (L) (85 ± 2% DDA, ~500kDa, Dungeness 
Environmental, Bothell, WA) was hydrated with dIH2O one day prior to use and used to 
manufacture half of the scaffold formulations with a final concentration of 1%. For 
composite scaffolds containing growth factor, 10 µg rhBMP-2 (0.35 g/mL) (PeproTech, 
Rocky Hill, NJ) was added to fiber-meshes by complete adsorption of rhBMP-2 prior to 
mixing into composite formulations. Vancomycin hydrochloride (MP Biomedical, Solon, 
OH) was added into the CS at 2% wt (CS:H2O ratio of 4:1) directly before mixing into a 
scaffold. All scaffolds were made by combining CS or CS and CL with chitosan meshes 
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into a mold and thoroughly mixing for 40 stirs in 20 seconds. The mold was tapped 20 
times on the bench to remove air bubbles and allowed to set for 1 hour at room 
temperature. All elution samples were prepared in a silicone mold 6.4mm diameter x 
15mm high (n=5/group). Seven scaffold compositions were evaluated, Table 1. 
 
Table 1: Scaffold compositions.  
Group Vancomycin loaded CS 
rhBMP-2 loaded 
chitosan Mesh %* 
1% chitosan 
Lactate 
C (control) X   
CL 
(control) 
X  X 
M (control)  4  
C4M X 4  
C7M X 7  
CL4M X 4 X 
CL7M X 7 X 
*Set tests used α-chymotrypsin as a model for of rhBMP-2 
 
Mechanical Tests 
Set time, compression and three-point bending experiments were performed to 
evaluate mechanical properties of the scaffolds based on the addition of chitosan fiber-
meshes, calcium lactate, and incorporation of therapeutic agents.   
Viacat Hardness Set Test 
A set test adapted from Doty et al. and ASTM Standard C472.26 was performed with 
the Viacat apparatus (Standard Test Methods for Physical Testing of Gypsum, Gypsum 
Plasters and Gypsum Concrete, ASTM, Inc., PA, USA) 39. In the test, the distance the 
Viacat needle (1mm diameter) penetrates the surface of the specimen was measured 
every 30 seconds. The time at which the needle penetrated less than ½ the height of the 
sample was used as the set time. Tests were performed in triplicate. Mixing dishes 37mm 
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diameter x 12 mm high were used to manufacture test specimens to provide sufficient 
area for repeated Viacat needle penetration measurements tests. α-chymotrypsin (from 
bovine pancreas, Sigma, St. Louis, MO) was used in place of rhBMP-2 for these tests due 
to the high amount of protein needed for the large specimen size. α-chymotrypsin was 
used as a model for rhBMP-2 since the MW and pI for the two proteins are similar: α-
chymotrypsin, MW: 25kDa, pI:  8.725 (Sigma-Aldrich Product Info), rhBMP-2, MW: 
26kDa (PeproTech Product Info) and pI: 8.2-8.66 23,46–48. 
Compression Test 
For compression tests, stainless steel molds of 6mm diameter x 12mm long were used 
to manufacture test and control specimens. Two plates were placed on top and on the 
bottom of the mold and the plates were secured with clamps. After 1 hour the top and 
bottom plates were removed and the surfaces were made flat with a razor blade and 
samples were removed from the mold. Samples were stored at room temperature until 
testing. The samples were tested on an MTS Insight 50 Test System using Testworks 4 
software and a 5kN load cell and an adjustable anvil to accommodate non-parallel 
specimen ends. Samples were tested with the longitudinal axis in a vertical orientation at 
a displacement rate of 0.33 mm/sec until failure. The software automatically stopped the 
compression test when loads over 1000N dropped more to than 20% of the peak force 
(N). Controls were performed in replicates of 8, while all other experimental groups 
containing rhBMP-2 were tested in triplicate. Reported values for compression tests were 
normalized to present a material property independent of the scaffold shape. The 
maximum force, F, was used to calculate the ultimate compressive strength (UCS), σUCS 
= F/A where A = cross sectional area. The compressive modulus (MPa) was determined 
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from the linear part of the force displacement curve and the strain energy density (MJ/m3) 
was calculated from the area under the stress strain curve up to the failure point. The 
failure point was defined as the maximum stress for samples with a brittle fracture, and at 
2% strain for samples with extended mechanical integrity. The 2% strain cut off point for 
the area under the curve calculation was based on features in the stress strain curves. 
Three-Point Bend Test 
Three-point bending test specimens were made using silicon molds with dimensions 
6.4 mm diameter and 44 mm long. After 1 hour samples were removed and stored at 
room temperature until testing. Tests were performed using an Instron Model 33R 4465 
with Bluehill® Software. A fixture span of 30 mm, crosshead speed of 1 mm/min, and a 
500N load cell were used. Tests were stopped when the load dropped more than 40%. 
Control and lactate containing experimental groups were tested in triplicate and non-
lactate experimental groups were tested in quadruplicate. The load at break (N) was 
recorded and flexural strength, σfs, (MPa) calculated based on Eq 1. The work (J) was 
determined by calculating the area under the load displacement curve up to the failure 
point. The failure point was defined as the maximum load for samples with a brittle 
fracture, and at a displacement of 0.19 mm for samples with extended mechanical 
integrity. The cutoff point of 0.19 mm was chosen because that was the displacement for 
other samples that had a brittle fracture break. 
 
!!" = !!!!!!                                                                 (1) 
 
Where Fm= maximum load, L = length of support span, R = radius of cylinder.  
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Antibiotic Elution, Growth Factor Elution, and Scaffold Degradation 
The concentration of eluted rhBMP-2 and vancomycin from the scaffolds was 
evaluated by placing scaffolds (n =5/group) in 1.6 mL of high glucose DMEM at 37oC. 
Eluates were collected every day for 6 weeks and stored at -80oC until analyzed. At every 
collection, the medium was completely replaced with fresh medium. Eluates were 
measured with an Enzyme-Linked Immunosorbent Assay (ELISA) (PeproTech, Rocky 
Hill, NJ) and Fluorescence Polarization Immunoassay (FPIA) (TDxFLx, Abbott 
Laboratories) to detect rhBMP-2 and vancomycin respectively 39,49,50. Additionally, 4 
samples were prepared as described in section 2 similar to C7M using fluorescently 
labeled rhBMP-2 to observe the location and retention of growth factor in the scaffold at 
2, 4 and 6 weeks. rhBMP-2 was fluorescently tagged with Alexa Fluor® 568 (Molecular 
Probes, Inc. Eugene, OR) following manufacturer’s instructions using a Micro Bio-
Spin® column (Bio-Rad, Hercules, CA). Scaffolds were incubated in DMEM with 
medium changes and at day 0, 2, 4 and 6 weeks (n=1/time point) were cut into 2mm 
slices with an IsoMet 100 precision saw and diamond blade (Buehler, Lake Bluff, IL) and 
visualized with a confocal microscope (Nikon Ti-E A1rSi) with TRITC filter. Samples 
were normalized to a control composed of the same scaffold material but containing no 
labeled protein. Mass of the scaffold was recorded prior to and post elution. Percent 
degradation, and therapeutic agent release were calculated with Eqs. (2) and Eqs. (3) 
respectively. 
 
% !"#$%&%'()* =  !"#$#%& !"##!!"#$% !"##!"#$#%& !"## ∗ 100                               (2) 
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% !ℎ!"#$%&'( !"#$% !"#$%"!& = 100− !!!!!!! ∗ 100                                (3) 
 
Where TL = Theoretical amount of loaded therapeutic agent and TC = Cumulative 
therapeutic agent release over 42 days. The theoretical amount of both rhBMP-2 and 
vancomycin was calculated based on the amount that was loaded into each scaffold. 
Antibiotic Activity 
The antibacterial activity of eluted vancomycin was tested by turbidity assays as 
previously described 39,49. Briefly, tubes containing 1.75 mL of trypticase soy broth 
(TSB) were inoculated with 25 µL containing ~2x106 colony forming units (CFU) of 
Staphylococcus aureus (Cowan I strain, ATCC 12598, Manassas, VA) and 200 µL of 
scaffold eluates. Control tubes were made with 1.75 mL TSB, 200 µL of DMEM 
medium, and either 25 µL of S. aureus (positive) or 25 µL of TSB (negative). Tubes were 
incubated overnight at 37oC and the turbidity was measured spectrophotometrically 
(Spectronic Instruments, 20 Genesis) at OD530. Optical density (OD) values < 0.05 were 
considered as “no-growth”.  
Statistical Analysis 
Statistical analysis was performed with ANOVA for all mechanical tests and 
degradation analysis. Factorial analysis of variance was used to determine effects of the 
presence of lactate, and percentage of mesh on the release of drugs from the composite 
scaffolds over time. When statistical differences were detected, post hoc analysis was 
carried out with Student –Newman-Keuls (SNK, P<0.05). Statistical analysis of turbidity 
results were performed with a proportions test using contingency tables for the rate of 
inhibition of growth with a Fishers Exact test. When normality assumptions were violated 
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for ANOVA tests, a non-parametric Kruskal-Wallis test was performed. Statistical 
analyses were conducted using SigmaPlot 12.5 at α = 0.05 level of significance.   
Results 
Chitosan Fiber-Mesh and Scaffold Fabrication 
Wet spun chitosan meshes exhibited fibers diameters of 129 ± 16 µm after air-drying. 
The air-dried meshes were stiff and brittle until hydrated. The mixing of CS-chitosan 
mesh scaffolds resulted in a wet-slurry that could not be manipulated by hand. When CL 
was added to the scaffolds, a dough-like material was rapidly formed and was easily 
manipulated by hand.  Slurries and dough were easily added to molds and after drying 
scaffolds maintained their shape when removed from molds. The dry molded scaffolds 
were robust and did not crumble when handled (Fig. 1).  
 
 
Fig. 1 Digital microscopy images (Keyence VHX-1000) of calcium sulfate powder (a), 
chitosan fiber-mesh (b), and side and top view of cylindrical composite pellet of chitosan 




 Mechanical tests 
Viacat Hardness Set Test 
The Viacat set test resulted in set times between 10-42 minutes depending on scaffold 
composition (Fig. 2). A two-way ANOVA indicated that there were significant 
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interaction between wt% of chitosan mesh and the use of chitosan lactate. Subsequent 
analysis indicated that the addition of chitosan lactate caused a significant reduction in set 
time of the CL group as compared to the CS control (p<0.001). Similarly, the presence of 
lactate caused a reduction in set time for both the 4 and 7% mesh composites (p<0.001). 
However, there was no effect on set time between the 4 and 7% mesh composites either 
with or without chitosan lactate (p=0.09).  Interestingly, set times were statically greater 
for mesh composites without lactate as compared to plain CS controls (p<0.001).  
 
 
Fig 2. Set time as determined by Vicat, in minutes. All groups are statistically different 






Representative force-displacement curves and fractured specimens from compression 
tests are shown in Fig. 3. The control (C and CL) test specimen exhibited typical brittle 
behavior, in which specimens fractured and lost mechanical integrity rapidly after 
exceeding peak loading forces (Fig. 3a, 3c). The visible fracture pattern for control 
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samples (Fig. 3a) showed cracking at the top and through the sample, but did not shatter 
in the test frame. Upon removing from the test frame, scaffolds did break into several 
pieces (not shown). However, when meshes were incorporated in the CS matrix, the 
specimens were able to continue to maintain some mechanical integrity after peak 
loading forces. These samples exhibited crushing type failures (Fig. 3b, 3d) and did not 
further break upon removal from the test frame.  
 
 
Fig. 3 Fracture patters (a, b) and representative force displacement curves (c, d) of 
scaffolds after compression. Representative break patterns of (a) control samples (C, CL), 
chipping on top exterior is noticeable, (b) chitosan mesh containing scaffolds (C4M, 
C7M, CL4M and CL7M), sample is crushed and chitosan mesh is visible, (c) force 
displacement curve for control samples, brittle break (d) force displacement curve for 




Values for UCS, compressive modulus and the strain energy density are shown in Fig. 
4. Scaffolds containing mesh exhibited significantly lower UCS and compressive moduli 
compared to controls, C and CL (p<0.001). C exhibited the highest UCS and compressive 
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modulus compared to all other groups (p<0.001). There were statistically significant 
interactions between mesh and chitosan lactate presence within UCS and strain energy 
density analysis. Further analysis of UCS revealed some difference within the groups 
containing mesh, but these differences were small compared to the differences between 
the controls. The compressive modulus for CL7M was lower than all other mesh 
containing groups (p<0.003). In contrast to the large difference found between controls 
and mesh containing scaffolds for UCS and compressive modulus, the strain energy 
density from scaffolds containing 4% mesh were similar to that of the CS without lactate 
control group. The strain energy density was lowest for the 7% mesh groups and the CS 
with lactate control. The CL and 7% mesh groups had the lowest strain energy densities 
(p<0.050) though C7M was not statistically different from the C4M (p = 0.065).  
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Fig. 4 The effect of chitosan mesh and chitosan lactate on mechanical properties from 
compression tests. (a) UCS (MPa), (b) compressive modulus (MPa), (c) strain energy 
density (MJ/m3). Dashed lines indicate the statistical differences across all groups unless 






Three-Point Bend Test  
Representative force-displacement curves and fractured specimen for three-point bend 
tests are shown in Fig. 5. Fig. 5a and 5c show the brittle break typical of control samples. 
Scaffolds that contained meshes remained intact after fracture (Fig. 5b), but a fracture 
could be seen while the specimens were in the test frame. Mesh containing scaffolds had 
force displacement curves represented in Fig. 5d, 6 samples had brittle fractures (d1), 2 
samples had a small break followed by extended mechanical integrity (d2), and 4 samples 
had jagged breaks (d3).  
 
 
Fig. 5 Fracture patters (a, b) and representative force displacement curves (c, d) of 
scaffolds after three-point bending tests. Break patterns of (a) control samples (C, CL) 
exhibited brittle breaks, (b) chitosan mesh containing scaffolds (C4M, C7M, CL4M and 
CL7M) showed no visible break after test completion though specimen did crack during 
testing. Representative force displacement curves showed a brittle break for control 
samples (c) and three different types of fractures for mesh containing scaffold ranging 
from brittle break (d1, n = 6), to small break followed by extended mechanical integrity 
(d2, n=2), or jagged break (d3, n=4).   
  
 
Similar to the compressive test results, the three-point bending results showed 
decreasing load at break and flexural strength as the chitosan mesh percentage increased 
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(Fig. 6). However, the presence of chitosan lactate did not seem to have any effect on 
scaffolds in three-point bending. The control groups had statistically higher loads and 
flexural strengths at break compared to mesh containing groups p<0.001 (Fig. 6a, 6b). 
The scaffolds with 4% mesh had higher loads at break and flexural strengths than 
scaffolds containing 7% mesh (p<0.01). There were no statistically significant differences 




Fig. 6 The effect of chitosan mesh and chitosan lactate on mechanical properties from 
three-point bend tests. (a) Load at break (N), (b) flexural strength (MPa), (c) work (10-3 
J). Dashed lines indicate the statistical differences across all groups. Symbols indicate 




Antibiotic Elution, Growth Factor Elution, and Scaffold Degradation 
All scaffolds exhibited a typical burst release of vancomycin on the first day followed 
by a decrease in elution thereafter (Fig. 7). Statistical analysis found that the release of 
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vancomycin from scaffolds was dependent on both the wt% of chitosan mesh and 
presence of chitosan lactate. To evaluate the scaffolds, subsequent factorial analyses were 
performed for groups at individual time points. The elution from CL7M was statistically 
different from all other groups on day 2 and from some other groups at days 3 and 4 (Fig. 
7a). Similarly CL4M eluted more vancomycin than various other groups on days 4, and 
days 7 to 14 (p<0.05). However the general trend was that CL7M exhibited the highest 
vancomycin release over the first 4 days and fastest release compared to other groups 
such that by day 10 the elution levels were negligible. Scaffolds containing 4% mesh 
exhibited a longer and higher vancomycin release (day 6-20) as compared to the 7% 
mesh groups. The control scaffolds (scaffolds without mesh) exhibited the longest elution 
release profiles with the highest vancomycin release from days 8-42 (p<0.05). 
Vancomycin recovery was 98% at: day 7, 8 for CL7M, CLM; day 12, 17 for C4M, 
CL4M; day 17 for both C, CL. The total recovery of vancomycin from all control and test 
composite scaffolds ranged between 81-90% (Table 2).  
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Fig. 7 Vancomycin elution from composite scaffold. (a) Day 1-10 (b) day 11-30. 




Table 2 Scaffold growth factor/antibiotic recovery, and % degradation over 6 weeks.  
Group % BMP Recovery 
% Vancomycin 
Recovery % Degradation  
C4M 1.13 ± 0.01 88 ± 3 83 ± 3 
C7M 1.04 ± 0.01 81 ± 8 83 ± 2 
CL4M 0.69 ± 0.01 91 ± 18 65 ± 13 
CL7M 0.89 ± 0.01 91 ± 16 68 ± 15 
C na 93 ± 5 72 ± 2 
CL na 77 ± 5 71 ± 1 
M 10.63 ± 0.04 na nd 
na = not applicable because drug not in scaffold. nd = not determined, determined for 
composite scaffolds only.   
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Results of rhBMP-2 release from scaffolds and chitosan mesh are shown in Fig. 8. 
Chitosan mesh samples loaded with rhBMP-2 but not incorporated into CS, exhibited a 
burst release on day 1 and a non-uniform but degrading release rate over 42 days (Fig. 
8a). Comparatively, all the rhBMP-2 loaded mesh that were incorporated into the CS 
exhibited a gradual increase in rhBMP-2 release over the first 5-7 days followed by a 
more sustained low-level release over the remainder of the study (Fig. 8b). By day 23, the 
rhBMP-2 release from M was similar to the levels recorded for the composite scaffolds. 
Initially lower levels of rhBMP-2 were released from scaffolds containing chitosan 
lactate (d3-18), but statistical differences were not detected at every time point, nor did 
they follow a consistent pattern. No statistical differences were found in the elution of 
rhBMP-2 after day 23 for any groups. The total recovery of rhBMP-2 from the composite 
scaffolds (~1%) and chitosan mesh (~10%) was very low (Table 2). Images from 
scaffolds with fluorescently tagged rhBMP-2 showed rhBMP-2 remained in scaffolds 




Fig. 8 Elution of rhBMP-2 from all composite scaffolds over 42 days (a) control 
compared to composite scaffolds (b) composite scaffolds only, (c) confocal microscope 
image from scaffolds loaded with fluorescently labeled rhBMP-2, arrows indicate 
chitosan mesh and black space is calcium sulfate.    
 
 
While not statically significant, the scaffolds containing chitosan mesh but no chitosan 
lactate (C4M/C7M) appeared to degrade more (~82%) than the control groups (~71%), 
indicating that the mesh contribute to the scaffold degradation (Fig. 9 and Table 2). 
Additionally, CL4M and CL7M were not statistically different from controls, and did not 
expose as much of the chitosan mesh as C4M/C7M did (Fig. 9). Statistically significant 
differences were found between C4M-CL4M (p=0.008) and C7M-CL7M (p=0.029) but 




Fig. 9 Digital microscopy images (Keyence VHX-1000) of degraded scaffolds after 42-




The eluates from scaffolds without mesh (C, CL) had the longest duration of inhibiting 
growth of S. aureus at 22 ± 4 days compared to all other groups (Fig. 10). The inhibition 
from C and CL was statistically significant (p=0.02) for all groups except CL4M. The 
elution from scaffolds with 4% mesh exhibited longer bacterial inhibition (16 ± 4 days) 
over scaffolds with 7% mesh, but only the groups with chitosan lactate (CL4M/CL7M) 
were statistically different (p=0.027). Groups containing 7% mesh (C7M, CL7M) had the 
lowest duration of bacterial inhibition of growth averaging 10 ± 2 days.  
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Fig. 10 The length of time that the eluates from all scaffolds inhibited growth of S. 




The challenge in developing materials to treat infected bone defects is to 1) load 
and deliver maximally active therapeutic concentrations with minimal doses to eliminate 
infection while stimulate bone growth, 2) maintain mechanical integrity to allow for bone 
regeneration and tissue ingrowth, and 3) allow customization to accommodate the needs 
of individual patients. To address these needs the present work evaluated the effects of 
chitosan mesh and chitosan lactate incorporation into a CS matrix on mechanical 
properties, antibiotic and growth factor elution, and antibiotic activity. To the best of our 
knowledge this is the first study to evaluate the mechanical properties and dual-elution 
properties of a therapeutically loaded CS - chitosan mesh scaffold. 
CS was evaluated in this study since it is a well-known bone scaffold material that 
facilitates new bone regeneration and has good drug delivery properties 26–29,31,51. We also 
incorporated chitosan in both fiber-mesh and gel form since it is a versatile biomaterial 
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lactate with the CS scaffolds had a clear effect on increasing set time in our study which 
is not surprising since it has been used to help make fast-setting and washout resistant 
CPC scaffolds by reducing the fluid penetration into the scaffold 53–55. Additionally, 
chitosan has been used as a binder for scaffold materials and has been found to increase 
mechanical properties in CPC cements 36,40,53,56–58. We found the presence of chitosan 
lactate did not consistently aid or inhibit the binding of chitosan fiber-mesh to the CS 
matrix as determined by mechanical tests, but instead increased the handleability through 
the formation of a workable dough, which could be of benefit in the operating room. The 
incorporation of higher percentages of mesh into the scaffolds resulted in increased 
pathways along which fluid could penetrate into scaffold, increasing drug release and 
dissolution of the scaffolds. The pathways created by the fibers increase the porosity of 
the bulk material, and increased porosity has been reported to increased drug elution as 
well as degradation59–63. This is supported by our findings of increased vancomycin 
elution from scaffolds as mesh percentages increased in the scaffolds, and by the change 
in degradation from surface erosion as seen in control samples compared to bulk 
degradation seen with mesh containing scaffolds. Some of the variation in our 
degradation and antibiotic elution results were likely a result of hand making our 
scaffolds. This is attributed to the fact that the chitosan lactate groups set faster than other 
groups, giving less time for mixing and thus perhaps were less uniform. However, in the 
setting of an operating room, the ability to manipulate a material by hand and into a non-
uniform wound void may be more advantageous than making uniform samples.   
The fracture break patterns of samples in compression were similar to those 
reported by Zhao et al., where there was non-catastrophic failure followed by an extended 
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ability to withstand a load 64. The three-point bending data clearly demonstrated the 
ability of the chitosan mesh scaffolds to remain intact after fracture, which would be 
beneficial in a wound to increase break/washout resistance and to be able to deliver drugs 
at the specific area of need. The difference between percentages of chitosan mesh was 
most clearly seen in the load to break and flexural strength from three-point bending 
tests, with 4% scaffolds being stronger than 7% scaffolds. Pan et al. also found a decrease 
in flexural strength with an increase in chitosan fibers in a CPC scaffolds likely because 
of non-uniformly distribute fibers and high air voids 65.  
We found that after incorporation of both the chitosan mesh and the chitosan 
lactate, there were no improvements over control groups in compression or three-point 
bending properties unlike other studies that found higher compressive and flexural 
strengths for chitosan fiber reinforced scaffolds compared to controls 42–44. We suspect 
that this is because the surface area of our chitosan mesh is much larger than that of 
individual fibers and may not have integrated as well with the CS. Only in the strain 
energy density for compression and work for three-point bending did some chitosan mesh 
and chitosan lactate containing scaffolds have similar properties to those of chitosan 
sulfate controls, indicating a benefit in chitosan mesh incorporation. The flexural strength 
(16-18 MPa) and UCS (22-28 MPa) for scaffolds containing 4% mesh were very similar 
to reported values of flexural strength (7-10 MPa) for poly(D,L-lactide-co-glycolide)–
CPC scaffold and of UCS (33 MPa) for chitosan fiber reinforced- CPC cements 
respectively 43,66. While these strengths are significantly lower than the reported 
compressive strengths required for femur defects or vertebra spacers (133 MPa), they are 
still applicable for non-load bearing orthopaedic and craniofacial applications 66,67.  
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The vancomycin elution for all groups exhibited a typical burst release followed 
by a prolonged decay, as reported in other studies 39,68–70. CL7M had the quickest elution 
over the first few days, possibly due to an increased porosity associated with the meshes 
and a possible interaction with chitosan lactate. For 7% M groups, the eluted vancomycin 
levels fell below the MIC for S. aureus (0.5-1µg/mL) between day 18-19, between day 
20-25 for 4% M groups and between day 27-30 for controls, suggesting that the porosity 
introduced by the addition of meshes aided in the faster vancomycin release from the 
interior of the scaffold in a proportional manner to that of percent chitosan mesh 
incorporation. Despite this, our measured antibiotic release does fall within range of 
reported antibiotic elution from CS scaffolds, 3-42 days, as reported in the literature 
39,68,69,71,72. This widely reported elution range is caused by several factors such as amount 
of drug loaded and sampling frequency. Taking samples every day compared to certain 
intervals will prevent drug build up in the eluent that can lead to high antibiotic data at 
later time points 39. While sampling every day does not reflect how elution and fluid 
would behave in a wound, it helps give a better idea of the daily drug dose that would be 
eluted from a scaffold in vitro.  
As indicative by the vancomycin elution, activity against S. aureus was the 
longest for control groups, and the shortest for 7% M scaffolds, a result from the 
increased porosity with the addition of chitosan mesh. In a previous study vancomycin 
elution from scaffolds containing chitosan microspheres were found to be active against 
S. aureus for 18 days 39 compared to 10-17 days for 4% and 7% M containing scaffolds. 
The discrepancy in activity is a result of the daily elution collection compared to interval 
collection. The activity of eluted antibiotic was not within the target 4-6 weeks period for 
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antibiotic treatment of orthopaedic wounds, also due to the collection frequency. A 
limitation of this work is that scaffolds were not tested in an infected model, but we 
suspect that scaffolds loaded with 4% mesh would show extended antibiotic activity and 
be helpful in preventing infection in a fracture site.  
As reported in a previous study from our group, CS matrix acted as a barrier for 
rhBMP-2 release and eliminated typical burst release patterns in the first days as seen in 
delivery systems such as collagen sponges 18,39,73. While rhBMP-2 acts on 
osteoprogenetor cells that arrive about one week after a fracture, it is also involved in the 
early recruitment of mesenchymal stem cells, thus a couple of days delay would be 
beneficial in a fracture site74–77. An extended rhBMP-2 elution was seen for all groups 
during the study, and elution levels, 0.2-6.19ng/day, and percent recovery, 0.69-1.13%, 
were similar to those reported in previous research from CS-chitosan rhBMP-2 loaded-
microsphere scaffolds, 0.18-4.48ng/day and 0.98-1.17% respectively39. The use  of 
chitosan mesh in the scaffolds resulted in only a slight increase in elution rate, but no 
increase in overall recovery of the rhBMP-2 was seen. Despite this, the extended growth 
factor elution may be beneficial in fracture wounds because literature has suggested that 
extended rhBMP-2 release is better at augmenting fracture healing than a single large 
bolus delivery of the growth factor 18,75,78,79. The low recovery of rhBMP-2 after 42 days 
indicates that the growth factor is likely being well retained by scaffold components, as 
rhBMP-2 is known to bind to calcium based scaffolds, as well as to chitosan materials 
due to ionic charges between the chitosan and rhBMP-2 36,57,58. The high 
binding/retention to chitosan is supported in this work by our visual detection of the 
fluorescently labeled rhBMP-2 on chitosan meshes embedded in CS over 6 weeks. Zhao 
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et al. also reported low recovery of rhBMP-2, 8.8%, for CPC-chitosan scaffolds 
containing rhBMP-2 loaded alginate microbeads after 20 days, which is comparable to 
the recovery, we found for group M, 10.63% 80. The high retention and low release of 
BMP-2 in vitro may be similar to physiological growth factor production and perhaps 
lead to improved bone filling and formation within large defect areas over time without 
the risk of high dosing and over production of bone. The activity of eluted rhBMP-2 was 
not determined in vitro due to high osmolality in eluates from the CS degradation, which 
interferes with the cellular assay. Thus, future work should evaluate the ability of this 
scaffold to stimulate bone growth in vivo. Though not specifically evaluated in this study, 
it is anticipated that there would be minimal to no interference of released vancomycin on 
the activity of rhBMP-2. This is because only very high levels of vancomycin (1800-3000 
µg/mL) have been reported to interfere with rhBMP-2 during the initial release time 
points in vitro 39. At these first time points there was little to no rhBMP-2 detected and at 
day 3, when rhBMP-2 release was beginning, vancomycin levels were reduced to non-
inhibitory levels (<1500 µg/ml)39. Thus, another advantage of the delayed release of 
BMP-2 is preserving the function of growth factor in the presence of initially high doses 
of antibiotics.  
Conclusion 
This study demonstrated the potential of a CS-chitosan mesh scaffold to be used 
as a combination drug delivery device to aid in infection control and new bone growth in 
a musculoskeletal wound. Although the calcium lactate did not enhance the binding 
between the chitosan mesh and calcium sulfate, it did have an unexpected benefit of 
increasing the handleablility of the scaffold before setting, which may be advantageous 
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for a surgeon in the operating room. Despite the reduction in mechanical strengths of 
scaffolds containing chitosan meshes, the strengths were similar to those of other 
reported fiber-reinforced scaffolds, and applicable for non-load bearing fractures. 
Additionally, the incorporation of meshes improved the ability of the scaffold to remain 
intact under some loading conditions, which is beneficial to prevent scaffold breakage 
and delivery of therapeutics to unwanted areas. The inclusion of chitosan-mesh did affect 
the vancomycin elution by increasing the rate of elution with increasing mesh percentage. 
Likewise, the scaffolds with meshes exhibited shorter duration of bacterial inhibition 
compared to controls, but were still effective against S. aureus for over 10 days. The 
growth factor elution did not appear to be affected by the different percentages of 
chitosan mesh incorporation in part because the rhBMP-2 appeared to remain tightly 
bound to the chitosan for the duration of the study. Mixing the mesh into the CS 
eliminated the typical burst release of rhBMP-2, and contributed to the continuous and 
sustained delivery over 6 weeks. Overall, the incorporation of 4% mesh was more 
advantageous with respect to mechanical strength, vancomycin elution and bacterial 












































































































































































































































 In chapter 2, the study of single and dual loaded antibiotics from a calcium sulfate–
chitosan-nHA composite scaffold showed that the vancomycin elution from the dual 
loaded scaffold had the longest inhibition of S. aureus (34 days) compared to all other 
groups. In contrast, the amikacin elution was only effective in the inhibition of P. 
aeruginosa for 24 hours regardless of scaffold composition. Vancomycin, loaded into the 
calcium sulfate matrix part of the scaffold, was more effective at bacterial inhibition and 
elimination of S. aureus compared to amikacin because 20x more vancomycin was 
incorporated than amikacin. Both the vancomycin and amikacin antibiotic elution showed 
a lower burst release from all composite CS-chitosan microspheres on the first day 
compared to control scaffolds of CS. Additionally, extended elution from composite 
scaffolds was also achieved. These results indicate that 1) vancomycin was successfully 
delivered from the CS matrix and remained active for an extended time (27-34 days) 2) a 
delayed burst (1 day) and extended low-level therapeutic release (7-42 days above MIC 
for P. aeruginosa) was achieved from the amikacin loaded microspheres embedded in CS 
matrix. Even though the delayed amikacin release from composite scaffolds was not as 
successful for our intended application of antibacterial inhibition, it could be beneficial in 
an application where there was a need to deliver therapeutics in stages, rather than at the 
same time. This outcome led us to investigate the use of this scaffold with an antibiotic 
and a growth factor where reduced burst and extended release are thought to be an ideal 
delivery mechanism.  
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 The delivery of a growth factor, rhBMP-2, and an antibiotic, vancomycin, was 
investigated in chapter 3. Similar to the previous work in chapter 2, the vancomycin was 
able to inhibit and kill S. aureus for an extended time (18 days). However, the growth 
factor release from chitosan-nHA microspheres embedded in CS matrix was much less 
than that released from microspheres alone. The rhBMP-2 release showed a 2 day delay 
and extended low level elution throughout 42 days, but activity on W-20-17 mouse 
fibroblast cells were unsuccessful in predicting activity due to the high osmolality created 
by the dissolution of CS in the eluent. Mock solutions with rhBMP-2 and vancomycin 
showed that W-20-17 cells were viable in the presence of vancomycin at varying 
concentrations. Additionally, the ALP expression from cells increased with increasing 
rhBMP-2 concentrations in mock solutions but decreased in the presence of high 
vancomycin concentrations (1800-3600 µg/mL), suggesting that delayed rhBMP-2 
release during the first days of high antibiotic release would help minimize the loss of 
function of the growth factor. From the mock solution experiment, we determined that 
the activity of rhBMP-2 released from composite scaffolds would be difficult to detect in 
cell studies. The important outcomes of this work were 1) an extended and active 
antibiotic elution from the composite scaffolds 2) a delayed burst and extended rhBMP-2 
release from microspheres embedded in the scaffolds 3) eluted levels of rhBMP-2 from 
composites might not be high enough to produce a measurable cellular response in vitro. 
These findings directed us to investigate other delivery systems that might increase the 
level of rhBMP-2 released without compromising the beneficial therapeutic release 
kinetics of the scaffold.  
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 We investigated a calcium sulfate composite with chitosan fiber-mesh to improve the 
rhBMP-2 elution, in chapter 4. Based on literature of fiber-reinforced composites we 
were also interested to know if any mechanical properties would be gained by the 
incorporation of fibers into the composite scaffold. Chitosan lactate, used as a binding 
agent, was found to improve the handleability of the scaffold but did not show consistent 
results in improving scaffold properties for compression or three-point bend tests. 
Overall, the mechanical properties of the scaffolds decreased with increasing percent of 
chitosan mesh incorporation. Composite scaffolds with meshes were comparable to 
controls in the work required for fracture and the strain energy density, and did have 
better break properties because the meshes held the scaffolds together. The elution of the 
composite scaffolds changed from a surface type degradation to a bulk degradation, 
which indicates increased porosity with the addition of fiber-mesh into the composite. 
The vancomycin elution and activity from the composite scaffolds ranged from 10-22 
days depending on scaffold composition, but the rhBMP-2 levels did not show a 
significant increase in release over the previous study. It was confirmed by fluorescently 
labeled rhBMP-2 loaded into composite scaffolds that the growth factor is retained by the 
scaffold after 6 weeks.  
 In summary, incorporation of the chitosan mesh 1) increased the vancomycin elution 
from the composite compared, 2) did not increase the rhBMP-2 elution from the 
composite, 3) did not improve the mechanical strength of the scaffolds 4) kept the 
scaffold intact during mechanical tests, 5) changed the degradation of the scaffold. While 
these results are interesting, further optimization on chitosan fiber-mesh is needed to 
control elution and degradation. Additionally, there may be a potential advantage of the 
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retention and low elution of rhBMP-2 from the scaffold. It is possible that this release 
would be similar to the natural biological response of BMP-2 since is normally present in 
bone tissue and active as necessary throughout the bone regeneration process. Evaluation 
in a small animal model would be necessary to investigate this further.  
 In conclusion, these experiments demonstrate partial achievement of our original 
hypothesis to show adequate antibiotic and growth factor elution for infection control and 
cellular indication of active growth factor. We were able to demonstrate extended 
antibiotic and growth factor elution, but we were only able to evaluate the antibiotic 
activity and were not able to increase the growth factor elution or evaluate the growth 
factor activity in vitro. While additional work is needed to improve growth factor release, 
the indication that rhBMP-2 remains in the scaffold over 6 weeks and is being slowly 
released throughout the study suggest that in vivo there is a potential to stimulate bone 
growth over an extended time frame. The use of a chitosan fiber-mesh may be 
advantageous over chitosan microspheres because they provide a path by which elution, 
degradation, and tissue ingrowth could occur. The ease of fabrication of composite 
scaffolds, elution results and mechanical tests indicate that using this scaffold could 
prevent the need for supraphysiological doses of growth factor, deliver sustained active 
antibiotic, maintain a 3D structure during wound healing, and be customizable by the 
surgeon in the operating room. Thus, development of a composite ceramic-degradable 
polymer device does demonstrate unique properties and advantages over other scaffold 




RECOMMENDATIONS FOR FUTURE WORK 
 A challenge we faced in this work was detecting the activity of rhBMP-2 in vitro. We 
attempted filtering, diluting and dialyzing our elution samples to remove the free calcium 
and sulfate ions. However, we were unsuccessful because, the eluents continued to be 
overwhelmed by the increased osmolality from CS degradation in cell culture, or the 
growth factor was diluted too low to stimulate any kind of response. We also tested an 
agarose overlay method with eluents on filter papers, but again we were unsuccessful to 
establish a robust method to detect lower levels of activity. Even if we could have 
performed the cellular work, it is doubtful that any response would have been achieved 
since the levels of rhBMP-2 eluted were below the typical detection limit. Thus, to 
overcome this limitation of our work, in vivo testing is needed. Using a soft tissue pouch 
model in a rat or mouse, the osteoinductive properties of the scaffold could be evaluated. 
A small animal model, such as a rabbit radial model, with a critical size defect could 
evaluate the ability to grow new bone into a defect area. Likewise, an infected-defect in a 
rabbit radius model would be necessary to determine both the antibiotic and regenerative 
properties of the graft.  
 Additionally, the composition of the scaffold could be further investigated. Chitosan 
nanospheres could be evaluated in place of the microspheres, or chitosan fibers in place 
of the fiber-mesh. Or the method of scaffold composition could be altered, such as 
chitosan fibers pre-wet with chitosan lactate for better integration with CS. Composite 
ceramic material could also be investigated instead of CS alone. The delivery properties 
of other therapeutic agents should also be investigated because ideally, this scaffold 
would be customizable with various antibiotics such as daptomycin, linezolid, 
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tobramycin, gentamicin or cefazolin or growth factors, such as BMP-7 or vascular 
endothelial growth factor depending on the need of the patient. Further in vitro testing 
could also be carried out with other bacteria such as Escherichia coli, Staphylococcus 
epidermidis or Streptococcus pyogenes to determine effectiveness against a broader 
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